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1. Summary	  
Several	   clinical	   and	  epidemiological	   studies	  have	  shown	   the	   inverse	   relationship	  
between	  HDL	  cholesterol	  and	  apolipoprotein	  A-­‐I	   (apoA-­‐I)	  plasma	   levels	  with	  the	  
risk	  of	  coronary	  artery	  disease.	  In	  line	  with	  this,	  HDL	  and	  apoA-­‐I	  exert	  many	  anti-­‐
inflammatory,	  anti-­‐oxidative	  and	  cytoprotective	  activities	  both	  in	  vitro	  and	  in	  vivo	  
that	  may	  confer	  atheroprotection.	  The	  classical	  anti-­‐atherogenic	  function	  of	  HDL	  is	  
described	   by	   the	   reverse	   cholesterol	   transport	   model.	   According	   to	   this	   model,	  
HDL	  mediates	   cholesterol	   efflux	   from	   cholesterol-­‐laden	  macrophages	  within	   the	  
arterial	  wall	   and	   returns	   it	   to	   the	   liver	   for	   excretion	   into	   the	   bile.	   The	   resulting	  
decrease	   in	  cholesterol	  accumulation	   is	   thought	   to	  prevent	   the	  development	  and	  
progression	  or	  even	  induce	  regression	  of	  atherosclerosis.	  	  
We	  have	  previously	  shown	  by	  biochemical	  and	  microscopic	  studies	  that	  cultivated	  
bovine	  aortic	  endothelial	  cells	  bind,	   internalize,	  and	  transcytose	  both	  apoA-­‐I	  and	  
HDL	   in	   a	   saturable	   and	   temperature-­‐dependent	   manner.	   By	   using	   RNA	  
interference	   and	   apoA-­‐I	   mutants,	   we	   demonstrated	   that	   transendothelial	  
transport	  of	  lipid-­‐free	  apoA-­‐I	  requires	  the	  interaction	  of	  the	  ATP-­‐binding	  cassette	  
A1	   (ABCA1),	   thus	   underlining	   the	   specificity	   of	   the	   transport.	   In	   addition,	   we	  
showed	  that	  the	  transendothelial	  apoA-­‐I	  transport	  is	  a	  two-­‐step	  process	  in	  which	  
apoA-­‐I	  is	  initially	  lipidated	  by	  ABCA1	  and	  then	  further	  processed	  by	  mechanisms	  
that	  are	  independent	  of	  ABCA1,	  but	  involve	  ABCG1,	  the	  scavenger	  receptor	  BI	  (SR-­‐
BI),	  and	  the	  endothelial	  lipase	  (EL).	  Thus,	  after	  lipidation,	  initially	  lipid-­‐free	  apoA-­‐I	  
and	  mature	  HDL	  particles	  are	  trafficked	  by	  the	  same	  pathway	  through	  endothelial	  
cells.	  These	  findings	  suggest	  that	  endothelial	  ABCA1	  plays	  a	  major	  role	   in	  apoA-­‐I	  
transport	   through	  endothelial	   cells.	  To	   investigate	   the	  physiological	   relevance	  of	  
transendothelial	  apoA-­‐I	  transport	  and	  its	  regulation	  by	  ABCA1,	  we	  generated	  and	  
characterized	  an	  endothelium-­‐specific	  Abca1	  knockout	  mouse	  model	  (Abca1e-­‐/-­‐)	  
by	  expressing	  the	  Cre	  recombinase	  under	  the	  control	  of	   the	  VE-­‐cadherin	  gene	   in	  
Abca1	  flox/flox	  mice.	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After	  confirming	  the	  specificity	  of	   the	  knockout	  by	  western	  blot	  and	  RT-­‐PCR,	  we	  
started	  to	  phenotype	  the	  mice.	  Bodyweight,	  as	  well	  as	  plasma	  levels	  of	  lipids	  and	  
lipoproteins	  of	  Abca1e-­‐/-­‐	  mice,	  were	  similar	  to	  control	  mice	  after	  chow	  or	  on	  high-­‐
fat	   diet	   feeding	   and	   after	   crossbreeding	   with	   LDL-­‐receptor	   knockout	   (Ldlr-­‐/-­‐)	  
mice.	  Interestingly,	  however,	  Abca1e-­‐/-­‐	  x	  Ldlr-­‐/-­‐	  double	  knockout	  mice	  showed	  a	  
significant	   increase	   in	   atherosclerotic	   lesions	   compared	   to	   Ldlr-­‐/-­‐	   control	   mice	  
after	  16	  weeks	  of	  high-­‐fat	  diet	  feeding,	  suggested	  by	  lipid	  staining	  of	  the	  aorta	  and	  
the	  aortic	  valve.	  We	  did	  not	  observe	  any	  difference	  in	  CD68	  positive	  macrophages	  
in	  the	  plaque	  of	  control	  and	  knockout	  mice.	  
We	   then	   investigated	   how	   the	   absence	   of	   ABCA1	   affects	   endothelial	  
vasorelaxation.	  By	  testing	  the	  aortic	  rings	  of	  Abca1e-­‐/-­‐	  mice,	  in	  an	  organ	  chamber,	  
we	   showed	   that	   the	   endothelium-­‐dependent	   vasorelaxation	   was	   significantly	  
reduced	   in	   Abca1e-­‐/-­‐	   mice.	   However,	   we	   did	   not	   observe	   any	   increase	   in	  
monocyte	   adhesion	   to	   the	   intact	   aortic	   endothelium	   of	   Abca1e-­‐/-­‐	   mice	   ex	   vivo	  
compared	  to	  control	  mice.	  	  
We	   further	   characterized	   apoA-­‐I	   and	   HDL	   metabolism	   by	   in	   vivo	   kinetics	  
experiments.	  Intravenous	  injection	  of	  wild	  type	  125I-­‐apoA-­‐I	  or	  125I-­‐HDL,	  but	  not	  of	  
a	   mutant	   125I-­‐apoA-­‐I	   with	   defective	   ABCA1	   interaction,	   LDL	   or	   albumin,	   led	   to	  
significantly	  reduced	  enrichment	  of	  the	  radiolabel	   in	  the	  aorta	  of	  Abca1e-­‐/-­‐	  mice	  
as	   compared	   to	   control	  mice.	   These	   findings	   led	   us	   to	   investigate	   the	   effects	   of	  
absent	   ABCA1	   in	   the	   microvasculature,	   notably	   the	   lymphatics.	  
Immunofluorescence	   staining	   of	   the	   lymphatics	   of	   the	   Abca1e-­‐/-­‐	   mice	   did	   not	  
reveal	   any	   particular	   changes	   in	   structure	   compared	   to	   control	  mice.	   The	   same	  
observation	   was	   made	   when	   studying	   the	   lymphatic	   function	   as	   lymphatic	  
clearance	  of	  apoA-­‐I	  out	  of	  the	  footpad	  or	  the	  peritoneum	  was	  not	  affected	  by	  the	  
lack	  of	  endothelial	  ABCA1.	  	  Macrophage	  to	  feces	  reverse	  cholesterol	  transport	  was	  
also	  not	  altered	  in	  Abca1e-­‐/-­‐	  mice.	  As	  an	  interesting	  and	  unexpected	  side	  finding,	  
we	  observed	  an	  improved	  glucose	  tolerance	  of	  Abca1e-­‐/-­‐	  mice.	  
In	   conclusion,	   our	   data	   suggest	   that	   endothelial	   ABCA1	   exerts	   local	   anti-­‐
atherogenic	   effects,	   possibly	   by	   modulating	   vasoreactivity	   and	   transendothelial	  





Im	  Zuge	  mehrerer	  klinischer	  und	  epidemiologischer	  Studien	  konnte	  eine	  negative	  
Korrelation	   zwischen	   den	   Plasmaspiegeln	   an	   HDL-­‐Cholesterin	   sowie	  
Apolipoprotein	   A-­‐I	   (apoA-­‐I)	   und	   dem	   Risiko	   der	   koronaren	   Herzerkrankung	  
nachgewiesen	  werden.	   Im	  Einklang	  mit	  diesen,	  üben	  HDL	  und	  ApoA-­‐I	   sowohl	   in	  
vitro	   als	   auch	   in	   vivo	   zahlreiche	   entzündungshemmende,	   antioxidative	   und	  
zellschützende	  Aktivitäten	  aus,	  die	  atheroprotektiv	  wirken	  können.	  Die	  klassische	  
antiatherogene	   Funktion	   des	   HDL	   wird	   durch	   das	   Modell	   des	   Cholesterin-­‐
Rücktransports	  beschrieben.	  Nach	  diesem	  Modell	  vermittelt	  HDL	  einen	  Rückfluss	  
des	  Cholesterins	  aus	  cholesterinbeladenen	  Makrophagen	  in	  der	  Arterienwand	  und	  
gibt	   dieses	   im	   Anschluss	   an	   die	   Leber	   ab,	   wo	   das	   Cholesterin	   mit	   der	   Galle	  
ausgeschieden	  wird.	  Es	  wird	  vermutet,	  dass	  die	  daraus	  resultierende	  Abnahme	  an	  
akkumulierendem	  Cholesterin	  sowohl	  die	  Entwicklung	  als	  auch	  das	  Fortschreiten	  
der	  Atherosklerose	  hemmt,	  und	  sogar	  deren	  Rückbildung	  induzieren	  kann.	  
In	  unserer	  Arbeitsgruppe	  konnte	  bereits	  durch	  biochemische	  und	  mikroskopische	  
Untersuchungen	   gezeigt	   werden,	   dass	   sowohl	   apoA-­‐I,	   als	   auch	   	   HDL	   in	   einer	  
sättigbaren	   und	   temperaturabhängigen	   Weise	   von	   kultivierten	   Aorta-­‐
Endothelzellen	   aus	   Rindern	   gebunden,	   internalisiert	   und	   transportiert	   wird.	  
Durch	   die	   Verwendung	   von	   RNA-­‐Interferenz	   und	   apoA-­‐I-­‐Mutanten	   konnten	   wir	  
ebenfalls	  nachweisen,	  dass	  der	  transendotheliale	  Transport	  von	  lipidfreiem	  apoA-­‐
I	  eine	  Interaktion	  mit	  der	  ATP-­‐binding	  Cassette	  A1	  (ABCA1)	  erfordert	  und	  somit	  
die	  Spezifität	  des	  Transports	  zusätzlich	  unterstreicht.	  Darüber	  hinaus	  konnte	  der	  
transendotheliale	  Transport	  von	  apoA-­‐I	  als	  ein	  zweistufiger	  Prozess	  nachgewiesen	  
werden,	   bei	   dem	   apoA-­‐I	   zunächst	   von	  ABCA1	   lipidiert	   und	   im	  Anschluss	  weiter	  
durch	  ABCA1-­‐unabhängige	  Mechanismen	  verarbeitet	  wird,	  die	  jedoch	  ABCG1,	  den	  
Scavenger-­‐Receptor-­‐B1	   (SR-­‐B1)	   und	   die	   Endothelial	   Lipase	   (EL)	   beinhalten.	  
Demzufolge	  wird,	   nach	   erfolgter	   Lipidierung,	   ursprünglich	   lipidfreies	   apoA-­‐I	  mit	  
Hilfe	   desselben	   Mechanismus	   wie	   reife	   HDL-­‐Partikel	   durch	   Endothelzellen	  
transportiert.	  Diese	  Ergebnisse	  legen	  nahe,	  dass	  ABCA1	  eine	  entscheidende	  Rolle	  
im	   Transport	   von	   apoA-­‐I	   durch	   Endothelzellen	   spielt.	   Um	   die	   physiologische	  
Relevanz	  des	  transendothelialen	  apoA-­‐I	  Transports	  und	  dessen	  Regulation	  durch	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4	  
ABCA1	   zu	   untersuchen,	   generierten	   und	   charakterisierten	   wir	   ein	   Endothel-­‐
spezifisches	   ABCA1	   Knockout-­‐Mausmodell	   (Abca1e-­‐/-­‐),	   in	   welchem	   die	   Cre-­‐
Rekombinase	   unter	   der	   Kontrolle	   des	   VE-­‐Cadherin-­‐Gens	   in	   ABCA1	   flox	   /	   flox	  
Mäusen	  exprimiert	  wird.	  	  
Nachdem	  die	  Spezifität	  des	  Knockouts	  durch	  Western-­‐Blot	  und	  RT-­‐PCR	  bestätigt	  
werden	   konnte,	   wurden	   die	   Mäusen	   phänotypisiert.	   Körpergewicht,	   sowie	   die	  
Lipid-­‐	  und	  Lipoprotein-­‐Plasmaspiegel	  von	  Abca1e-­‐/-­‐	  und	  Kontrollmäusen	  zeigten	  
hierbei	  nach	  normaler	  oder	  fettreicher	  Diät,	  genauso	  wie	  nach	  erfolgter	  Kreuzung	  
mit	  LDL-­‐Rezeptor	  Knockout	  (Ldlr-­‐/-­‐)	  Mäusen	  ähnliche	  Werte.	  Interessanterweise	  
zeigten	   Abca1e-­‐/-­‐	   x	   Ldlr-­‐/-­‐	   Doppel-­‐Knockout-­‐Mäuse	   im	   Vergleich	   zu	   Ldlr-­‐/-­‐	  
Mäusen	  in	  einer	  Lipidfärbung	  der	  Aorta	  und	  Aortenklappe	  nach	  16	  Wochen	  jedoch	  
eine	   signifikante	   Zunahme	   an	   athereosklerotischen	   Läsionen,	   wenn	   diese	   einer	  
fettreichen	  Diät	  ausgesetzt	  waren.	  In	  CD68-­‐positiven	  Makrophagen	  aus	  der	  Plaque	  
von	   Kontroll-­‐	   und	   Knockout-­‐Mäusen	   konnten	   hingegen	   keine	   Unterschiede	  
festgestellt	  werden.	  	  
Im	   Anschluss	   hieran	   wurde	   die	   endotheliale	   Dysfunktion	   der	   Knockout-­‐Mäuse	  
getestet,	   um	   zu	   überprüfen,	   ob	   ein	   Fehlen	   von	   ABCA1	   die	   endotheliale	  
Vasorelaxation	  beeinflussen	  würde.	  Hierbei	  wurden	  Ringe	  der	  Aorta	  von	  Abca1e-­‐
/-­‐	  Mäusen	  in	  einer	  Organkammer	  getestet	  und	  es	  konnte	  gezeigt	  werden,	  dass	  die	  
Endothel-­‐abhängige	   Vasorelaxation	   signifikant	   in	   Abca1e-­‐/-­‐	   reduziert	   war.	  
Allerdings	   konnte	   kein	   Anstieg	   der	   Monozyten-­‐Adhäsion	   an	   das	   intakte	  
Aortenendothel	   von	   Abca1e-­‐/-­‐	  Mäusen	   ex	   vivo	   im	   Vergleich	   zu	   Kontrollmäusen	  
festgestellt	  werden.	  
Des	  Weiteren	  wurde	  der	  Metabolismus	  von	  apoA-­‐I	  und	  HDL	  durch	  in	  vivo	  Kinetik	  
Experimente	   charakterisiert.	   Die	   intravenöse	   Injektion	   von	   Wildtyp	   125I-­‐apoA-­‐I	  
oder	  125I-­‐HDL	  führte	  zu	  einer	  deutlich	  reduzierten	  Anreicherung	  des	  radioaktiven	  
Markers	  in	  der	  Aorta	  von	  Abca1e-­‐/-­‐	  Mäusen	  im	  Vergleich	  zu	  Kontrollmäusen.	  Dies	  
war	   jedoch	   nicht	   der	   Fall	   wenn	   ein	   mutiertes	   125I-­‐apoA-­‐I	   mit	   defekter	   ABCA1	  
Interaktion,	  LDL	  oder	  Albumin	  zum	  Einsatz	  kam.	  Diese	  Ergebnisse	   führten	  dazu,	  
dass	   im	   Anschluss	   die	   Wirkung	   von	   fehlendem	   ABCA1	   in	   der	   Mikrovaskulatur,	  
insbesondere	  in	  den	  Lymphgefäßen	  untersucht	  wurde.	  Immunfluoreszenzfärbung	  
der	   Lymphgefäße	   der	   Abca1e-­‐/-­‐	   Mäuse	   zeigte	   keine	   besonderen	   strukturellen	  
Zusammenfassung	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Veränderungen	  im	  Vergleich	  zu	  Kontrollmäusen.	  Die	  gleiche	  Beobachtung	  wurde	  
bei	   der	   Untersuchung	   der	   lymphatischen	   Funktion	   gemacht,	   wobei	   der	  
lymphatische	   Abtransport	   von	   apoA-­‐I	   aus	   dem	   Fußballen	   oder	   dem	   Bauchfell	  
nicht	  durch	  das	  Fehlen	  der	  endothelialen	  ABCA1	  betroffen	  war.	  Der	  Cholesterin-­‐
Rücktransport	   von	  Makrophagen	   zum	   Fäzes	  war	   in	   Abca1e-­‐/-­‐	  Mäusen	   ebenfalls	  
nicht	   beeinflusst.	   Unerwarteter-­‐,	   aber	   interessanterweise	   konnten	   wir	   bei	   den	  
Abca1e-­‐/-­‐	  Mäusen	  außerdem	  eine	  erhöhte	  Glucosetoleranz	  feststellen.	  
Zusammenfassend	   deuten	   unsere	   Daten	   darauf	   hin,	   dass	   endotheliale	   ABCA1	  
einen	   lokalen	   anti-­‐atherogenen	   Effekt	   ausübt,	   der	   möglicherweise	   durch	  
Modulation	   von	   Vasoreaktivität	   und	   transendothelialem	   Transport	   von	   apoA-­‐I	  
und	  HDL	  entsteht.	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3. List	  of	  Abbreviations	  
ABC	   	   	   	   ATP-­‐binding	  cassette	  transporter	  
ABCA1	   	   	   ATP-­‐binding	  cassette	  transporter	  A1	  
ABCG1	   	   	   ATP-­‐binding	  cassette	  transporter	  G1	  
acetyl	  CoA	   	   	   Acetyl	  coenzyme	  A	  
ADP	   	   	   	   Adenosine	  diphosphate	  
apo	   	   	   	   Apolipoprotein	  
ATP	   	   	   	   Adenosine	  triphosphate	  
BSA	   	   	   	   Bovine	  serum	  albumin	  
CAD	   	   	   	   Cardiovascular	  disease	  	  
CD31	  	   	   	   	   Cluster	  of	  differentiation	  31	  	  
CETP	   	   	   	   Cholesteryl	  ester	  transfer	  protein	  
cpm	   	   	   	   Counts	  per	  minute	  
CTL	   	   	   	   Control	  
DMEM	  	   	   	   Dulbecco's	  modified	  Eagle	  medium	  
EC	  	   	   	   	   Endothelial	  cell	  
EL	  	   	   	   	   Endothelial	  lipase	  	  
eNOS	   	   	   	   Endothelial	  nitric	  oxide	  synthase	  
ER	   	   	   	   Endoplasmatic	  reticulum	  
FCS	   	   	   	   Fetal	  calf	  serum	  
FPLC	   	   	   	   Fast	  protein	  liquid	  chromatography	  
GTT	   	   	   	   Glucose	  tolerance	  test	  
HDL	   	   	   	   High-­‐density	  lipoproteins	  
HMG-­‐CoA	   	   	   3-­‐hydroxy-­‐3-­‐methylglutaryl	  CoA	  
ICAM-­‐I	   	   	   Intercellular	  adhesion	  molecule-­‐I	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IDL	   	   	   	   Intermediate	  low	  density	  lipoprotein	  
ITT	   	   	   	   Insulin	  tolerance	  test	  
kDa	   	   	   	   Kilo	  Dalton	  
LCAT	  	   	   	   	   Lecithin/cholesterol	  acyltransferase	  
LDL	  	   	   	   	   Low	  density	  lipoprotein	  	  
LDLR	  	   	   	   	   LDL	  receptor	  	  
LPL	  	   	   	   	   Lipoprotein	  lipase	  
LRP1	   	   	   	   LDL	  receptor-­‐related	  protein	  1	  
LXR	   	   	   	   Liver-­‐X-­‐receptor	  
MCP-­‐1	  	   	   	   Monocyte	  chemotactic	  protein-­‐1	  
Nitric	  oxide	   	   	   NO	  
oxLDL	  	   	   	   Oxidized	  LDL	  
PBS	   	   	   	   Phosphate	  buffered	  saline	  
PLTP	   	   	   	   Phospholipid	  transfer	  protein	  
S1P	   	   	   	   Sphingosine-­‐1-­‐phasphate	  
SDS-­‐PAGE	   	   	   SDS	  polyacrylamide	  gel	  electrophoresis	  
SRA	   	   	   	   Scavenger	  receptor	  A	  
SR-­‐BI	   	   	   	   Scavenger	  receptor	  type	  B1	  
TNF-­‐alpha	   	   	   Tumour	  necrosis	  factor	  alpha	  
TripA	   	   	   	   TripA-­‐ApoA-­‐I-­‐K9AK15A	  
VLDL	   	  	   	   	   Very	  low	  density	  lipoprotein	  
WT	   	   	   	   Wild-­‐type	  





Atherosclerosis	  is	  a	  chronic	  inflammatory	  vascular	  disease	  and	  remains	  the	  major	  
cause	   of	   death	   in	   westernized	   countries	   1.	   An	   important	   causal	   factor	   of	  
atherosclerosis	  is	  a	  high	  blood	  plasma	  concentration	  of	  cholesterol	  in	  the	  form	  of	  
low-­‐density	   lipoprotein	   (LDL).	   High	   LDL-­‐cholesterol	   plasma	   concentrations	  
increase	  myocardial	  infarction.	  LDL	  accumulates	  in	  the	  intima	  of	  arteries,	  where	  it	  
become	   susceptible	   to	   oxidation	   2.	   Oxidized	   LDL	   has	   several	   proatherogenic	  
properties.	   For	  example,	   it	   stimulates	   the	  upregulation	  of	  monocyte	   chemotactic	  
protein-­‐1	   (MCP-­‐1)	   production	   in	   endothelial	   cells,	  which	   act	   as	   chemoattractant	  
for	   monocytes.	   Oxidized	   LDL	   is	   also	   ingested	   by	   macrophages	   in	   the	   intima	   by	  
scavenger	   receptors	   A	   (SR-­‐A)	   and	   cluster	   of	   differentiation	   36	   (CD36),	   which,	  
unlike	  the	  LDL	  receptor	  are	  not	  regulated	  by	  cholesterol	  3.	  	  
Atherosclerosis	   is	   initiated	  by	  damage	  of	   the	  vascular	  endothelium.	  This	   in	   turn,	  
increases	  the	  expression	  of	  adhesion	  molecules	  on	  endothelial	  cells	  and	  decreases	  
their	   ability	   to	   release	  nitric	   oxide	   (NO)	   and	  other	   substances	   that	   help	  prevent	  
adhesion	   of	   macromolecules,	   platelets	   and	   monocytes	   to	   the	   endothelium.	  
Monocytes	   attach	   to	   endothelial	   cells	   at	   lesion-­‐prone	   sites	   of	   large	   arteries.	   The	  
monocytes	   cross	   the	   endothelium,	   enter	   the	   intima	   of	   the	   vessel	   wall,	   and	  
differentiate	   into	  macrophages	   3	   (Figure	   1A).	   In	  principle,	   this	  process	   could	  be	  
protective,	  because	  macrophages	  remove	  cytotoxic	  and	  proinflammatory	  modified	  
lipoproteins	   and	   apoptotic	   cells.	   However,	   once	   differentiated,	   the	  macrophages	  
ingest	  and	  oxidize	  the	  accumulated	  lipoproteins,	  giving	  the	  macrophages	  a	  foam-­‐
like	   appearance.	   These	   cells	   secrete	   various	   atherogenic	   molecules,	   including	  






With	  time,	  the	  fatty	  streaks	  grow	  larger,	  and	  the	  surrounding	  fibrous	  and	  smooth	  
muscle	   tissues	   proliferate	   to	   form	   larger	   plaques	   Figure	   1B.	   The	   macrophages	  
also	   release	   substances	   that	   cause	   inflammation	   and	   further	   proliferation	   of	  
smooth	  muscle	   and	   fibrous	   tissue	  within	   the	   arterial	  wall.	   The	   lipid	  deposit	   and	  
the	   cellular	   proliferation	   can	   become	   so	   large	   that	   the	   plaque	   bulges	   into	   the	  
lumen	  of	  the	  artery	  and	  greatly	  reduces	  blood	  flow	  4.	  The	  fibroblasts	  of	  the	  plaque	  
deposit	   extensive	   amounts	   of	   dense	   connective	   tissue,	   called	   sclerosis,	   which	  
becomes	  so	  great	  that	  the	  arteries	  become	  stiff.	  	  
Calcium	  salts	  often	  precipitate	  with	  the	  cholesterol	  and	  other	  lipids	  of	  the	  plaques,	  
leading	  to	  hard	  calcifications	  that	  render	  the	  artery	  rigid.	  Atherosclerotic	  arteries	  
lose	   their	   dispensability	   and	   become	   easily	   ruptured	   1,5–7.	   Plaque	   ruptures	  
generally	  occur	  at	   the	   shoulders	  of	   the	  plaques	  and	  most	  often	   in	   lesions	  with	  a	  
thin	   fibrous	   cap6.	   Additionally,	   matrix	   metalloproteinases	   secreted	   by	  




Figure	   1	   -­‐	   Development	   of	   atherosclerotic	   plaque.	   (A),	   Attachment	   of	   a	   monocyte	   to	   an	  
adhesion	   molecule	   on	   a	   damaged	   endothelial	   cell	   of	   an	   artery.	   The	   monocyte	   then	   migrates	  
through	   the	   endothelium	   into	   the	   intimal	   layer	   of	   the	   arterial	   wall	   and	   is	   transformed	   into	   a	  
macrophage.	   The	   macrophage	   then	   ingests	   and	   oxidizes	   lipoprotein	   molecules,	   becoming	   a	  
macrophage	   foam	  cell.	  The	   foam	  cells	   release	   substances	   that	   cause	   inflammation	  and	  growth	  of	  
the	  intimal	  layer.	  (B)	  Additional	  accumulation	  of	  macrophages	  and	  growth	  of	  the	  intima	  cause	  the	  
plaque	   to	   grow	   larger	   and	   accumulate	   lipids.	   Eventually,	   the	   plaque	   could	   rupture,	   causing	   the	  
blood	  in	  the	  artery	  to	  coagulate	  and	  form	  a	  thrombus.	  Adapted	  from	  9.	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4.2. Cholesterol	  metabolism	  	  
François	   Poulletier	   de	   la	   Salle	   first	   discovered	   cholesterol	   in	   1769.	   Its	   name	  
originates	  from	  greek	  chole	  (bile)	  and	  stereos	  (solid),	  as	  well	  as	  the	  chemical	  suffix	  
–ol	   for	   alcohol.	   Cholesterol	   is	   an	   important	   component	  of	   the	   eukaryotic	  plasma	  
membrane,	  where	  it	  helps	  to	  generate	  a	  semipermeable	  barrier	  between	  cellular	  
compartments	  and	  regulates	  membrane	  fluidity.	  It	  is	  also	  essential	  in	  humans	  for	  
the	  synthesis	  of	  bile	  acids,	  steroid	  hormones	  and	  vitamin	  D	  10.	  	  
	  
Figure	  2	  –	  Chemical	  structure	  of	  cholesterol	  
It	   is	   estimated	   that	   the	   ratio	   between	  de	  novo	   cholesterol	   synthesis	   and	   dietary	  
intake	  is	  of	  ≈	  70:30	  11.	  This	  value	  probably	  varies	  from	  individual	  to	  individual	  and	  
depends	   on	   genetic	   constitution	   and	   dietary	   supply.	   Cholesterol	   is	   mainly	  
synthesized	   by	   the	   liver	   and	   to	   some	   extent	   the	   intestine,	   adrenal	   glands	   and	  
reproductive	   organs.	   All	   nuclear	   cells	   can	   synthesize	   cholesterol	   from	   acetyl	  
Coenzyme	  A	  (acetyl	  CoA)	  through	  the	  mevalonate	  pathway.	  The	  rate-­‐limiting	  step	  
of	   this	  pathway	   is	   the	  conversion	  of	  3-­‐hydroxy-­‐3-­‐methylglutaryl	  CoA	  (HMG	  CoA)	  








4.2.1. Lipoprotein	  metabolism	  
Cholesterol	  is	  needed	  by	  every	  cell	  for	  different	  metabolic	  roles.	  Because	  the	  main	  
source	  of	  cholesterol	  is	  the	  liver	  and	  the	  intestine,	   it	  must	  be	  transported	  via	  the	  
bloodstream	   to	   be	   delivered	   to	   the	   cells.	   Due	   to	   the	   hydrophobic	   nature	   of	  
cholesterol,	   a	   carrier	   is	   needed	   to	   transport	   it	   in	   the	   blood.	   These	   carriers	   are	  
called	  lipoproteins	  and	  are	  composed	  of	  a	  protein	  and	  a	  lipid	  moiety.	  Lipoproteins	  
are	  classified	  and	  named	  according	  to	  their	  density	  (Table	  1).	  	  
Lipoprotein	   Density	  [g/ml]	   Diameter	  [nm]	   Apolipoproteins	  
Chylomicrons	   <	  0.95	   <	  1000	  
A-­‐I	  &	  A-­‐II,	  B48,	  C-­‐I,	  C-­‐II,	  C-­‐
III,	  E,	  H	  
VLDL	   0.95	  –	  1.006	   30	  -­‐	  80	   B100,	  C-­‐I,	  C-­‐II,	  C-­‐III,	  E	  
IDL	   1.006	  –	  1.019	   25	  -­‐	  50	   B100,	  C-­‐II,	  C-­‐III,	  E	  
LDL	   1.019	  –	  1.063	   18	  -­‐	  28	   B100	  
HDL	   1.063	  –	  1.21	   5	  -­‐	  15	  
A-­‐I,	  A-­‐II,	  A-­‐IV,	  C-­‐I,	  C-­‐II,	  C-­‐
III,	  C-­‐IV,	  D,	  E,	  F,	  H,	  J,	  L-­‐I,	  M	  
Table	  1	  –	  Lipoproteins	  classification	  
There	   are	   five	   major	   types,	   each	   assigned	   with	   different	   functions.	   The	  
chylomicrons	  are	   the	   largest	   lipoproteins.	  Their	  role	   is	   to	   transport	   triglycerides	  
from	   the	   intestine	   to	   the	   cardiac	   and	   skeletal	   muscles	   and	   adipose	   tissue	   for	  
energy	   usage	   and	   storage,	   respectively.	   Endothelial-­‐bound	   lipoprotein	   lipase	  
hydrolyses	   triglycerides	   in	   circulating	   chylomicrons	   to	   generate	   chylomicron	  
remnants.	  These	  particles	  can	  acquire	   lipids,	  particularly	  cholesteryl	  esters,	   from	  
high	   density	   lipoproteins	   (HDL)	   via	   the	   function	   of	   cholesteryl	   ester	   transfer	  
protein	   (CETP).	   Finally,	   these	   cholesteryl	   ester-­‐rich	   chylomicron	   remnants	   are	  
rapidly	   cleared	  by	   the	   liver.	  The	  very	   low	  density	   lipoproteins	   (VLDL)	   transport	  
triglycerides	  synthesized	  in	  the	  liver	  to	  the	  adipose	  and	  muscle	  tissue.	  The	  VLDL	  
remnants,	   so	   called	   intermediate	   density	   lipoproteins	   (IDL),	   are	   formed	   after	  
triglyceride	  hydrolysis	  and	  uptake	  of	  fatty	  acids	  by	  peripheral	  tissues.	  Low-­‐density	  
lipoproteins	   (LDL)	   deliver	   cholesterol	   to	   the	   liver	   and	   other	   cells	   by	   binding	   to	  
LDL	  receptors	  and	  endocytosis.	  The	  cells	  can	  stop	  the	  synthesis	  of	  LDL	  receptors,	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in	   case	   of	   sufficient	   supply	   of	   cholesterol,	   via	   the	   SREBP	   pathway.	   High-­‐density	  
lipoproteins	  (HDL)	  exert	  different	  functions.	  The	  classical	  role	  is	  to	  collect	  excess	  
peripheral	  cholesterol	  from	  the	  body’s	  cells	  and	  return	  it	  to	  the	  liver	  for	  recycling	  
and	  excretion	  via	  the	  bile	  into	  the	  digestive	  tract.	  	  
4.2.2. High	  density	  lipoprotein	  and	  Apolipoprotein	  A-­‐I	  
HDL	  is	  the	  smallest	  and	  densest	  of	  all	   lipoproteins.	   It	   is	  also	  the	  only	   lipoprotein	  
that	   does	   not	   contain	   apoB	   It	   originates	   as	   small	   discoidal-­‐shaped	   particles	  
generally	   composed	   of	   two	   apolipoproteins,	   predominantly	   apolipoprotein	   A-­‐I	  
(apoA-­‐I),	  complexed	  with	  phospholipids	  and	   free	  cholesterol.	  ApoA-­‐I	   is	  a	  28	  kDa	  
protein	  consisting	  of	  243	  amino	  acids	  and	  is	  synthesized	  and	  secreted	  by	  both	  the	  
liver	   and	   the	   intestine.	   The	   initially	   lipid-­‐free	   apoA-­‐I,	   also	   named	   pre-­‐β-­‐HDL,	   is	  
then	   lipidated	   with	   free	   cholesterol	   and	   phospholipids	   via	   interaction	   with	   the	  
ATP-­‐binding	  cassette	  A1	  (ABCA1)	   to	   form	  a	  disc-­‐shaped	  nascent	  HDL	  particle	  12.	  
The	  lecithin:cholesterol	  acyltransferase	  (LCAT)	  is	  an	  enzyme	  found	  in	  the	  plasma	  
compartment	  that	  binds	  to	  pre-­‐β-­‐HDL.	  It	  transfers	  the	  sn-­‐2	  acyl	  groups	  of	  lecithin	  
to	   free	   cholesterol	   generating	   esterified	   cholesterol	   and	   lysolecithin	   13.	   The	  
cholesteryl	  esters	  are	  apolar	  and	  therefore,	  move	  to	  the	  hydrophobic	  core	  of	   the	  
particle.	  This	  step	  converts	  the	  discoidal	  shaped	  HDL	  into	  a	  larger	  spherical	  HDL	  
particle,	  called	  HDL2	  or	  HDL3.	  Another	  enzyme,	  cholesteryl	  ester	   transfer	  protein	  
(CETP),	   transfers	   cholesteryl	   esters	   from	   HDL	   to	   apoB-­‐containing	   lipoproteins,	  
and	  vice	  versa	  transfers	  triglycerides	  from	  apoB-­‐containing	  lipoproteins	  to	  HDL	  14.	  
This	   leads	   to	   the	   formation	   of	   smaller	   sized	   HDL	   particles	   enriched	   in	  
triglycerides,	  but	  with	  a	  lower	  amount	  of	  cholesterol	  and	  apoA-­‐I	  15.	  It	  is	  important	  
to	  mention	  that	  not	  all	  species	  express	  CETP.	  For	  example,	  CETP	  is	  not	  present	  in	  
mice	  and	  rats	  16,	  and	  as	  a	  consequence,	  these	  animals	  have	  a	  very	  high	  level	  of	  HDL	  
cholesterol.	   The	   transfer	   of	   phospholipids	   from	   triglyceride-­‐rich	   lipoproteins	   to	  
HDL	   is	   accomplished	   by	   the	   phospholipid	   transfer	   protein	   (PLTP).	   PLTP	   is	   also	  
capable	  of	  fusing	  two	  intermediate	  size	  HDL	  particles,	  resulting	  in	  the	  formation	  of	  
larger	  HDL	  and	  the	  subsequent	  release	  of	  pre-­‐β-­‐HDL	  17.	  
HDL	  components	  can	  then	  be	  extracted	  from	  the	  body	  by	  the	  liver,	  the	  kidney	  and	  
steroidogenic	  tissues.	  It	   is	  important	  to	  mention	  that,	  HDL	  can	  selectively	  deliver	  
cholesteryl	   esters	   to	   cells	   without	   internalization	   and	   degradation	   of	   the	  whole	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HDL	   particle.	   This	   process	   is	   referred	   to	   as	   selective	   uptake	   and	   involves	   the	  
scavenger	   receptor	   BI	   (SR-­‐BI).	   However,	   HDL	   can	   also	   be	   removed	   from	   the	  
circulation	   via	   endocytic	   uptake	   of	   the	   entire	   particle	   by	   a	   process	   called	  
holoparticle	   endocytosis.	   Unfortunately,	   little	   is	   known	   about	   HDL	   holoparticle	  
uptake.	  Hepatic	  HDL	  endocytosis	  involves	  an	  ecto-­‐F1-­‐ATPase/P2Y13	  pathway	  18,19.	  	  
Binding	  of	  apoA-­‐I	  to	  ectopic	  beta	  chain	  of	  the	  mitochondrial	  F1	  ATP	  synthase	  on	  
the	   cell	   surface	   of	   hepatocytes	   triggers	   extracellular	   ATP	   hydrolysis	   18.	   The	  
generated	   ADP	   will	   then	   activate	   the	   nucleotide	   receptor	   P2Y13	   leading	   to	   the	  
internalization	   of	   HDL	   holoparticles.	   In	   vivo	   studies	   in	   mice	   demonstrated	   that	  
pharmacological	  activation	  of	  P2Y13	  with	  cangrelor	  promotes	  liver	  uptake	  of	  HDL	  
and	   biliary	   sterol	   output	   by	   an	   SR-­‐BI	   independent	   pathway	   20.	   Deficiency	   in	   the	  
P2Y13	  in	  mice	  reduced	  HDL	  uptake	  into	  the	  liver	  by	  20%	  20.	  However,	  HDL	  plasma	  
concentrations	   in	   P2Y13	   knockout	   mice	   remained	   unchanged	   20,	   possibly	   as	   a	  
result	  of	  a	  compensatory	  SR-­‐BI	  upregulation.	  
The	  kidney	  is	  the	  most	  important	  contributor	  to	  the	  clearance	  of	  circulation	  apoA-­‐
I	  and	  potentially	  HDL	  particles.	  The	  exact	  mechanism	  by	  which	  apoA-­‐I	  or	  HDL	  are	  
catabolized	   is	   not	   completely	   clear.	   However,	   some	   studies	   have	   shown	   that	  
cubilin	   is	   involved	   in	   renal	   uptake	   of	   HDL	   and	   apoA-­‐I	   21,22.	   These	   studies	   have	  
described	   high	   affinity	   binding	   of	   apoA-­‐I	   and	   HDL	   to	   cubilin,	   leading	   to	  
internalization	   and	   degradation	   in	   lysosome.	   Interestingly,	   apoA-­‐I	   excretion	   in	  
urine	  is	  higher	  in	  humans	  with	  a	  defective	  cubilin	  21.	  Additional	  findings	  imply	  that	  
megalin	  may	  assist	  in	  renal	  uptake	  of	  apoA-­‐I	  by	  acting	  as	  a	  co-­‐receptor	  of	  cubilin	  
23.	  A	  possible	  mechanism	  seems	  that	  apoA-­‐I	  and	  small	  HDL	  particles	  are	  removed	  
from	   the	   plasma	  by	   glomerular	   filtration	   and	   then	   avidly	   taken	   up	   by	   a	   cubilin-­‐










Figure	  3	  –	  HDL	  metabolism.	  Lipid-­‐free	  or	  lipid-­‐poor	  apoA-­‐I,	  synthesized	  and	  secreted	  by	  the	  liver	  
(and	  intestine),	  acquires	  phospholipids	  and	  free	  cholesterol	  from	  hepatic	  and	  peripheral	  tissues	  via	  
ABCA1.	  This	   leads	   to	   the	   formation	  of	  discoidal	  HDL	  particles	  (HDL	  disc),	  which	  undergo	   further	  
modification	   by	   lecithin:cholesterol	   acyltransferase	   (LCAT)	   and	   develop	   into	   spherically	   shaped	  
HDL2	   or	   HDL3,	   which	   in	   turn	   can	   act	   as	   acceptors	   for	   ABCG1-­‐mediated	   cholesterol	   efflux.	  
Cholesterol	  esters	  from	  mature	  HDL	  particles	  can	  be	  transferred	  to	  LDL	  by	  the	  action	  of	  cholesteryl	  
ester	   transfer	   protein	   (CETP).	   Phospholipids	   can	   be	   transferred	   by	   the	   phospholipid	   transfer	  
protein	  (PLTP).	  Finally,	  HDL	  cholesterol	   is	   taken	  up	  by	   the	   liver	   in	  a	  process	   that	   is	  mediated	  by	  









4.2.3. Anti-­‐atherogenic	  properties	  of	  HDL	  
Several	   clinical	   and	   epidemiological	   studies	   have	   shown	   an	   inverse	   relationship	  
between	  HDL	  and	  apoA-­‐I	  plasma	  levels	  and	  the	  risk	  of	  coronary	  artery	  disease	  25–
28.	  Therefore,	  HDL	  is	  sometimes	  referred	  to	  as	  the	  “good	  cholesterol”	  lipoprotein.	  
Clinicians	   advise	   to	  maintain	   the	   HDL	   level	   in	   the	   plasma	   above	   1	  mmol/l.	   The	  
positive	   effect	   of	   HDL	   and	   apoA-­‐I	   can	   be	   attributed	   to	   diverse	   atheroprotective	  
functions	   of	   these	   particles.	   One	   of	   these	   processes	   significantly	   affecting	  
atherosclerosis	   is	   the	   reverse	   cholesterol	   transport	   29,30,	   a	   pathway	   by	   which	  
cholesterol	   accumulated	   in	   the	   foam	   cells	   is	   transported	   from	   the	   vessel	  wall	   to	  
the	   liver	   for	   excretion	   or	   recycling	   31,32.	   The	   resulting	   decrease	   in	   cholesterol	  
accumulation	  is	  thought	  to	  prevent	  the	  development	  of	  atherosclerosis	  30.	  Besides	  
reverse	  cholesterol	  transport,	  other	  atheroprotective	  properties	  of	  HDL	  and	  apoA-­‐
I	   are	   known.	   In	   vitro	   and	   in	   vivo,	   native	   HDL	   and	   artificially	   reconstituted	   HDL	  
(rHDL),	  containing	  only	  apoA-­‐I	  and	  phospholipids	  show	  anti-­‐inflammatory	  effects,	  
e.g.	   by	   inhibiting	   the	   expression	   of	   cell	   adhesion	   molecules	   and	   thereby,	   the	  
transmigration	   of	   leukocytes	   through	   endothelial	   cells33–35.	   Furthermore,	   HDL	  
exert	   antithrombotic,	   antioxidant,	   antiapoptotic,	   and	   anticoagulatory	   properties	  
and	   are	   also	   able	   to	   maintain	   endothelial	   function	   and	   integrity	   by	   promoting	  
vasorelaxation,	   junction	   stability,	   proliferation,	   migration,	   recruitment,	   and	  
differentiation	  of	  endothelial	  progenitor	  cells	  36–38.	  There	  are	  indications	  that	  not	  
only	  the	  concentration	  of	  HDL	  in	  the	  plasma,	  but	  also	  the	  “quality”	  of	  HDLs	  is	  an	  
important	   factor	   for	   the	   antiatherogenity.	   For	   instance,	   the	   antiatherogenic	  
activity	  could	  be	  enhanced	  by	  different	  antioxidants	  (e.g.	  paraoxonase)	  carried	  by	  
HDL	  and	  reduced	  by	  the	  presence	  of	  oxidized	  lipids39.	  
It	   has	   been	   shown	   that	   native	   and	   reconstituted	   HDL	   are	   also	   effective	   anti-­‐
inflammatory	  agents	  40,41.	  Thus,	   the	   infusion	  of	  HDL	  or	  an	  HDL	  mimetic	  similarly	  
reduces	  vascular	   inflammation,	  providing	  a	  potential	  mechanism	  for	   intravenous	  
HDL	   therapy	   in	   reducing	   coronary	   atherosclerosis.	   For	   example,	   a	   study	   	   has	  
provided	   strong	   evidence	   that	   the	   infusion	   of	   HDL	   containing	   a	   variant	   form	   of	  
apoA-­‐I,	   namely	  apoA-­‐I	   Milano,	   which	   has	   been	   identified	   in	   individuals	   in	   rural	  
Italy	  who	  exhibit	  very	  low	  levels	  of	  HDL,	  would	  be	  effective	  in	  decreasing	  coronary	  
atherosclerosis	   42.	   For	   the	   combined	   36	   patients	   who	   received	   apoA-­‐I	   Milano	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infusions,	   total	   atheroma	   volume	   and	   the	   10-­‐mm	   most	   diseased	   segment	  
decreased	  compared	  with	  the	  atherosclerosis	  quantified	  at	  baseline.	  However,	  the	  
data	  were	   not	   significant	   compared	   to	   the	   saline	   control,	   as	   the	   population	   size	  
was	  too	  low.	  	  
Two	  additional	  HDL	  infusion	  clinical	  trials,	  the	  Effect	  of	  rHDL	  on	  Atherosclerosis–
Safety	  and	  Efficacy	  (ERASE)	  Trial	  43	  and	  Selective	  Delipidation	  Trial	  44,	  confirmed	  
that	   infusion	   of	   reconstituted	   HDL	   reduced	   coronary	   atherosclerosis.	   The	  
combined	  results	  from	  the	  acute	  HDL	  infusions	  studies	  add	  support	  to	  the	  concept	  
that	  increasing	  HDL	  may	  be	  an	  effective	  approach	  to	  reducing	  coronary	  atheroma	  
burden,	  with	   stabilization	   of	   the	   plaque	   and	   reduction	   in	   clinical	   cardiovascular	  
events.	  HDL	  is	  normally	  cardioprotective	  because	  of	  its	  ability	  to	  promote	  cellular	  
cholesterol	  efflux	  and	   to	  mediate	  RCT.	  However,	  HDL	  can	  become	  dysfunctional,	  
e.g.	   by	   posttranslational	   modification	   of	   apoA-­‐I	   45.	   Myeloperoxidase-­‐induced	  
oxidative	   damage	   of	   apoA-­‐I,	   which	   is	   seen	   in	   patients	   with	   established	  

















4.2.3.1. Macrophage	  cholesterol	  efflux	  and	  RCT	  
Reverse	  cholesterol	  transport	  is	  started	  by	  cholesterol	  efflux	  from	  macrophages	  of	  
the	  vessel	  wall,	  which	   is	   the	  only	  known	  mechanism	  by	  which	  macrophages	  can	  
reduce	  the	  cellular	  cholesterol	  accumulation	  46.	  The	  extracellular	  acceptors	  of	  the	  
effluxed	  cholesterol	  are	  HDL	  and	  apoA-­‐I	  47.	  The	  main	  cellular	   factors	   involved	   in	  
the	  cholesterol	  efflux	  are	  ABCA1,	  ABCG1,	  and	  SR-­‐BI.	  The	  current	  model	   indicates	  
that	   ABCA1-­‐mediated	   phospholipid	   efflux	   to	   initially	   lipid-­‐free	   apoA-­‐I	   generates	  
particles,	   which	   then	   interact	   with	   ABCG1	   and	   SR-­‐BI	   for	   enhanced	   cholesterol	  
efflux	  48–50.	  This	  process	  may	  involve	  uptake	  and	  resecretion	  of	  apoA-­‐I	  or	  HDL	  51–
53,	  the	  so-­‐called	  retro-­‐endocytosis.	  
To	   assay	   the	   macrophage	   specific	   RCT	   in	   mice,	   macrophages	   loaded	   with	   3H	  
cholesterol	   are	   injected	   intraperitoneally.	   Plasma	   samples	   are	   collected	  
periodically	   to	   measure	   the	   amount	   of	   radioactive	   cholesterol	   that	   has	   been	  
transported	   by	   HDL	   through	   the	   peritoneum	   into	   plasma.	   Feces	   are	   collected	  
continuously	   for	   measurement	   of	   3H	   neutral	   sterol	   and	   bile	   acids.	   Therefore,	  
appearance	   of	   tracer	   can	   be	   followed	   in	   plasma	   over	   time,	   and	   the	   amount	   of	  
macrophage-­‐derived	  radiolabeled	  tracer	  excreted	  in	  feces	  can	  be	  quantified	  as	  an	  
estimate	  of	  macrophage-­‐to-­‐feces	  RCT.	  Studies	  have	  shown,	  with	  this	  method,	  that	  
overexpression	   of	   apoA-­‐I	   promotes	   54	   and	   apoA-­‐I	   deficiency	   impairs	   55	  	  
macrophage	  RCT,	  consistent	  with	   the	  atheroprotective	  effect	  of	  apoA-­‐I.	   	  Multiple	  
studies	   have	   assessed	   macrophage	   specific	   RCT	   in	   the	   setting	   of	   genetic	   and	  
pharmacological	  manipulation	  of	  mice	  and	   the	  effect	  on	  RCT	  are	  consistent	  with	  
the	  effect	  of	   these	  manipulation	  of	  atherosclerosis	  development	  56.	  Recently,	   two	  
experimental	   studies	   have	   demonstrated	   that	   fecal	   cholesterol	   excretion	   is	   not	  
always	   a	   perquisite	   for	  macrophage	   cholesterol	   efflux.	   For	   example,	   injection	   of	  
reconstituted	   HDL	   stimulated	   cholesterol	   efflux	   to	   the	   liver	   without	   increasing	  
fecal	   excretion	   57.	   Intravenous	   infusion	   of	   the	   5A	   peptide,	   an	   apoA-­‐I	   mimetic	  
peptide,	   complexed	  with	   phospholipid	   increased	   cholesterol	   efflux,	  measured	   in	  
vivo	   by	   a	   stable	   isotope	   kinetic	   technique	   from	   ABCA1	   and	   ABCG1	   transfected	  
macrophage	  and	  reduced	  atherosclerosis	  in	  apoE	  knockout	  mice	  without	  altering	  




4.2.3.2. Anti-­‐inflammatory	  properties	  of	  HDL	  
A	  number	  of	  studies	  have	  described	  the	  anti-­‐inflammatory	  effects	  of	  HDL.	  One	  the	  
main	  features	  of	  HDL	  in	  this	  regard	  is	  its	  ability	  to	  limit	  cytokine-­‐induced	  adhesion	  
molecule	   expression	   on	   cultured	   endothelial	   cells	   33,59.	   The	   exact	   mechanism	   is	  
still	  not	  fully	  understood,	  however,	  it	  is	  believed	  that	  HDL	  perturbs	  tumor	  necrosis	  
factor	   (TNF)	   induced	   activation	   of	   the	   sphingosine	   kinase	   signal	   transduction	  
pathway	   in	   endothelial	   cells,	   leading	   to	   reduced	   extracellular	   signal-­‐regulated	  
kinases	  and	  nuclear	  factor	  κβ	  (NF-­‐κβ)	  cascade	  activity	  and	  ultimately	  to	  inhibition	  
of	   endothelial	   inflammation	   60.	   Inhibition	   of	   NF-­‐κβ-­‐mediated	   adhesion	  molecule	  
expression	   by	   HDL	   has	   been	   shown	   to	   involve	   SR-­‐BI,	   as	   well	   as	   sphinogine-­‐1-­‐
phosphate	  (S1P)	  61.	  
Recently,	   studies	   have	   shown	   that	   upregulation	   of	   3β-­‐hydroxysteroid-­‐Δ24	  
reductase	   expression	   in	   endothelial	   cells	   by	   HDL	   attenuates	   adhesion	   molecule	  
expression	  62.	  This	  potential	  of	  HDL	  to	  reduce	  adhesion	  molecule	  expression	  is	  lost	  
after	   silencing	   of	   3β-­‐hydroxysteroid-­‐Δ24	   with	   siRNA	   62.	   The	   anti-­‐inflammatory	  
effect	   of	   HDL	   appears	   to	   also	   be	   present	   in	   vivo.	   Two	   studies	   showed	   that	  
reconstituted	   HDL	   treatment	   reduced	   adhesion	   molecule	   expression	   in	   injured	  
arteries	   of	   apoE	   KO	  mice	   63	   or	   normocholesterolemic	   rabbits	   64.	   Similar	   effects	  
were	  observed	  in	  collared	  carotid	  arteries	  of	  chow	  fed	  rabbits	  after	   infusion	  of	  a	  
low	  dose	  of	  lipid-­‐free	  apoA-­‐I	  65.	  
HDL	  may	  also	   impede	  circulating	  monocytes	  and	  neutrophils	   to	  migrate	   into	   the	  
intima,	  one	  of	  the	  earliest	  events	  in	  atherosclerosis.	  HDL	  can	  also	  act	  on	  leukocyte	  
recruitment	   to	   the	   vascular	   wall	   by	   affecting	   chemotactic	   stimuli.	   These	  
observations	   are	   in	   keeping	  with	   other	   in	   vivo	  experiment,	   which	   revealed	   that	  
daily	   infusion	  of	   reconstituted	  HDL	   inhibits	  endothelial	  expression	  of	  monocytes	  
chemoattractant	  protein-­‐1	  induced	  by	  periarterial	  collar	  in	  rabbit	  carotid	  arteries	  
64.	   HDL	   restricts	   the	   expression	   of	   several	   other	   chemokines	   and	   their	   receptor	  






4.2.3.3. Vasoprotective	  properties	  of	  HDL	  
Another	   important	   role	   of	   HDL	   is	   its	   ability	   to	   preserve	   vascular	   function.	   HDL	  
regulates	   vascular	   tone	   by	   inducing	   nitric	   oxide	   (NO)	   bioavailability	   and	   in	   that	  
way	  endothelium	  dependent	  vasodilatation.	   Several	  mechanisms	  are	   involved	   to	  
initiate	  NO	  production	  by	  HDL.	  In	  cultured	  endothelial	  cells,	  HDL	  interaction	  with	  
SR-­‐BI	  was	  shown	  to	  increase	  endothelial	  nitric	  oxide	  synthase	  (eNOS)	  activity	  67.	  
HDL	   causes	  NO	   and	   endothelium	   dependent	   vasorelaxation	   in	   aortic	   rings	   from	  
wild-­‐type,	  but	  not	  SR-­‐BI	  knockout	  mice	  67.	  Other	  studies	  showed	  that	  HDL	  causes	  
NO	  release	  and	  vasodilatation	  via	  Akt-­‐mediated	  eNOS	  phosphorylation	  68.	  
In	   parallel,	   HDL	   activation	   of	   eNOS	   requires	   signaling	   through	   the	   PI3	   kinase-­‐
dependent	  MAP	   kinase	   pathway	   68.	   HDL	   has	   been	   shown	   to	   sustain	   eNOS	   in	   its	  
active	   dimeric	   form	   by	   inducing	   efflux	   of	   oxysterol	   7-­‐ketocholesterol	   from	  
endothelial	  cells	  in	  an	  ABCG1-­‐dependent	  manner	  69.	  Another	  mechanism	  by	  which	  
HDL	   regulates	  NO	   production	  may	   involve	   its	   impact	   on	   the	   abundance	   of	   total	  
eNOS	   protein.	   Exposure	   of	   endothelial	   cells	   to	   HDL	   induces	   eNOS	   protein	  
expression	   by	   extending	   the	   half-­‐life	   of	   the	   protein	   70.	   The	   lysophospolipid	  
receptor	   S1P3	   was	   identified	   as	   a	   key	   receptor	   participating	   in	   the	   eNOS-­‐
dependent	  vasorelaxing	  effect	  of	  HDL	  71.	   	  HDL	  may	  also	  play	  a	  role	   in	  regulating	  
vascular	   tone	   by	   increasing	   the	   release	   of	   the	   potent	   vasodilator	   prostacyclin	   72	  
and	   by	   antagonizing	   the	   vasoconstrictor	   effects	   of	   endothelin-­‐1	   73.	   In	   human,	  
intravenous	   injection	   of	   reconstituted	   HDL	   restores	   impaired	   endothelium	  
dependent	  vasodilation	  in	  hypercholesterolemic	  men	  74.	  
HDL	   has	   been	   found	   to	   also	   protect	   endothelial	   cells	   against	   cytotoxicity	   of	  
oxidized	   LDL	   (oxLDL)	   by	   interfering	   with	   disruption	   in	   calcium	   homeostasis	  
induced	   by	   oxLDL	   in	   bovine	   endothelial	   cells	   75.	   HDL	   also	   blocks	   the	   apoptotic	  
activity	  of	  TNF-­‐alpha	  through	  the	  modulation	  of	  caspase-­‐3	  protease	  activity	  76.	  	  
Endothelial	  cell	  proliferation	  and	  migration	  after	  vascular	  injury	  is	  a	  crucial	  step	  in	  
endothelial	   repair.	  Multiple	   in	  vitro	   studies	  have	   linked	  HDL	  and	  endothelial	   cell	  
proliferation	  77,78.	  The	  enhanced	  endothelial	  proliferation,	  caused	  by	  HDL,	  can	  be	  
due	  to	  chelating	  extracellular	  calcium	  79.	  Recent	  findings	  revealed	  that	  endothelial	  
cells	  migrate	   in	   response	   to	  HDL	  via	   SR-­‐BI	   initiated	   activation	  of	  Rac	  GTPase	   80.	  
Interestingly	   both	   apoA-­‐I	   and	   SR-­‐BI	   knockout	  mice	   exhibit	   a	   decreased	   capacity	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for	   re-­‐endothelialization	   after	   vascular	   injury	   80.	   HDL	   might	   also	   contribute	   to	  
endothelial	  repair	  by	  regulating	  endothelial	  progenitor	  cells.	  
In	   vitro	   studies	   have	   shown	   HDL	   impacting	   endothelial	   progenitor	   cells	   by	  
promoting	  differentiation	  and	  proliferation	  81–83,	  by	  preventing	  apoptosis	  83,84	  and	  
by	  enhancing	  adhesion	  to	  endothelial	  cells	  83.	  Studies	  have	  shown	  that	  infusion	  of	  
reconstituted	  HDL	  in	  mice	  improved	  the	  recovery	  of	  hind	  limb	  ischemia	  in	  terms	  
of	  the	  blood	  flow	  and	  capillary	  density	  81.	  Moreover,	  injection	  of	  reconstituted	  HDL	  
increased	  endothelial	  repair	  in	  injured	  aortic	  endothelium	  of	  apoE	  knockout	  mice	  
85.	   Mice	   overexpressing	   apoA-­‐I	   showed	   increased	   circulating	   endothelial	   cell	  

















4.3. 	  Cellular	  proteins	  interacting	  with	  HDL	  
4.3.1. ATP	  binding	  Cassette	  Transporter	  A1	  
ABCA1	  is	  a	  full	  trans-­‐membrane	  transporter	  of	  240-­‐kDA,	  comprising	  two	  analogue	  
structural	   units	   87.	   ABCA1	   is	   predominantly	   expressed	   in	   hepatocytes,	  
macrophages	  and	  astrocytes,	  as	  well	  as	  other	  cells	  types,	  such	  as	  endothelial	  cells.	  
The	   importance	   of	   ABCA1	   in	   cholesterol	   metabolism	   was	   first	   highlighted	   in	  
patients	   suffering	   from	   Tangier	   disease.	   These	   patients	   are	   characterized	   by	   a	  
dramatic	   reduction	   of	   HDL	   particle	   concentration	   in	   the	   plasma,	   as	   well	   as	  
cholesterol	  ester	  deposition,	   in	  various	  tissues	  especially	   the	  tonsils.	  An	   increase	  
of	   lipid-­‐free	   apoA-­‐I	   catabolism	   causes	   the	   reduction	   of	   HDL-­‐cholesterol	  
concentration.	  Tangier	  disease	  is	  caused	  by	  different	  mutations	  in	  the	  ABCA1	  gene	  
preventing	  correct	  protein	   folding	  or	  expression	   in	   the	  hepatocytes	   88.	  ABCA1-­‐/-­‐	  
mice	  show	  a	  similar	  phenotype	  as	  Tangier	  disease	  patients.	  Mice	  overexpressing	  
ABCA1	  have	  an	  elevated	  HDL	  concentration	  89.	  ABCA1	  expression	  is	  enhanced	  by	  
high	  cholesterol	  content	  of	  the	  cells	  and	  is	  regulated	  by	  the	  nuclear	  receptor	  liver	  
X	   receptor	   (LXR)90.	  ABCA1	   is	   responsible	   for	   the	   transport	  of	  phospholipids	  and	  
cholesterol	  to	  the	  external	  leaflet	  of	  the	  plasma	  membrane,	  where	  it	  is	  accessible	  
to	  lipid-­‐free	  or	  lipid-­‐poor	  apoA-­‐I,	  but	  not	  to	  mature	  HDL.	  
This	  process	  is	  best	  explained	  in	  hepatocytes	  and	  cholesterol	  loaded	  macrophages.	  
Our	   group	   recently	   demonstrated	   that	   in	   ECs	   ABCA1	   also	   lipidates	   apoA-­‐I	   91.	  
ABCA1	   is	   found	   in	   the	   intracellular	   compartment	   and	   on	   the	   cell	   surface.	   The	  
location	   for	   apoA-­‐I	   lipidation	   remains	   controversial.	   A	   first	   theory	   suggests	   that	  
ABCA1	   translocates	   cholesterol	   and	   phospholipids	   form	   the	   inner	   to	   the	   outer	  
membrane	   leaflet	  by	   forming	  a	   transport	   chamber	  with	   its	   two	   trans-­‐membrane	  
domains.	  Cholesterol	  and	  phospholipids	   then	   form	  a	   lipid	  domain	  on	   the	  plasma	  
membrane	   accessible	   for	   solubilisation	   by	   apoA-­‐I	   92.	   A	   second	  model,	   called	   the	  
retro-­‐endocytosis	  theory,	  suggests	  that	  apoA-­‐I	  binds	  to	  ABCA1	  and	  the	  complex	  is	  
internalized	   to	   intracellular	   lipids	   deposits	   where	   lipidation	   occurs	   before	  
exocytosis	   93,94.	   Previous	   studies	   by	   Chen	   et	   al.	   showed	   evidence	   that	   both	  




The	   role	   of	   ABCA1	   in	   the	   development	   of	   atherosclerosis	   has	   been	   intensively	  
studied.	  The	  association	  of	  Tangier	  disease	  with	  cardiovascular	  disease	  (CAD)	  has	  
been	   observed	   in	   some	   patients,	   but	   not	   in	   others	   96–99.	   Animal	   studies	   also	  
revealed	   controversial	   results.	   Aiello	   et	   al.	   demonstrated	   that	   ABCA1-­‐/-­‐	  mice	   or	  
mice	  with	  ABCA1-­‐/-­‐	  bone	  marrow	  transplantation	  have	  increased	  atherosclerotic	  
lesions	  100.	  However,	  several	  studies	  reported	  that,	  despite	  marked	  changes	  in	  the	  
plasma	   lipoprotein	   profiles	   and	  macrophage	   efflux,	   ABCA1-­‐/-­‐	   mice	   do	   not	   have	  
increased	   atherosclerosis	   89,101,102.	   In	   addition,	   several	   studies	   with	   mice	  
overexpressing	  ABCA1	  demonstrated	  a	  reduction	  of	  atherosclerosis	  genesis	  103–105. 
On	  the	  other	  hand,	  Joyce	  et	  al.	  reported	  a	  significant	  increase	  in	  atherosclerosis	  in	  
mice	   overexpressing	   ABCA1	   106.	   The	   combined	   results	   of	   studies	   in	   Tangier	  
disease	  patients,	  ABCA1-­‐/-­‐	  mice	  and	  mice	  overexpressing	  ABCA1	  indicate	  that	  the	  
effects	   of	   ABCA1	   on	   atherosclerogenesis	   are	   complex	   and	   require	   further	  
investigations.	   Taking	   all	   into	   account,	   ABCA1	   appears	   to	   play	   a	   central	   role	   in	  
HDL	   cholesterol	   metabolism	   by	   translocating	   phospholipids	   and	   cholesterol	  
across	  the	  plasma	  membrane	  bilayer	  and	  presenting	  them	  to	  apoA-­‐I,	  which	  binds	  
to	  ABCA1. 
	  
Figure	  4	  –	  Topological	  model	  of	  ABCA1.	  ABCA1	  belong	  to	  the	  ATP	  binding	  cassette	  transporter	  
family	   and	   consist	   of	   2	   6-­‐helix	   transmembrane	   domains	   and	   two	   nucleotide	   binding	   domain.	  
Adapted	  from	  107	  .	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4.3.1.1. ABCA1	  dependent	  cholesterol	  efflux	  pathway	  
The	   concentration	   of	   ABCA1	   present	   in	   the	   plasma	   membrane	   determines	   the	  
rates	  of	  free	  cholesterol	  efflux	  and	  HDL	  particle	  formation.	  The	  primary	  acceptor	  
for	  cellular	  cholesterol	  efflux	  via	  ABCA1	  is	  apoA-­‐I.	  The	  binding	  of	  apoA-­‐I	  to	  ABCA1	  
prevents	   its	   intracellular	   degradation	   and	   increases	   ABCA1	   expression	   in	   the	  
plasma	  membrane.	   ABCA1	   and	   apoA-­‐I	   interaction	   facilitates	   the	  mobilization	   of	  
cholesterol	   from	   the	   late	   endocytic	   compartment	   to	   the	   cell	  membrane	   108.	   The	  
apoA-­‐I/ABCA1	   interaction	   has	   been	   proposed	   to	   lead	   to	   solubilization	   of	   an	  
exovesiculated	   membrane	   domain,	   which	   results	   in	   the	   formation	   of	   a	  
heterogeneous	  population	  of	  nascent	  HDL	  particles	  that	  are	  discoidal	  in	  shape	  and	  
contain	  free	  cholesterol	  34,109.	  	  	  
4.3.1.2. ABCA1	  in	  liver	  and	  intestine	  
Generation	   of	   genetically	   engineered	  mice	   lacking	   or	   overexpressing	  ABCA1	  has	  
provided	  insight	  into	  the	  tissue	  specific	  function	  of	  ABCA1.	  It	  has	  been	  shown	  by	  
Timmins	  et	  al.	  110	  that	  mice	  lacking	  ABCA1,	  specifically	  in	  hepatocytes,	  display	  an	  
80	   %	   reduction	   in	   plasma	   HDL-­‐C.	   This	   finding	   indicates	   that	   liver	   ABCA1	  
determines	  the	  generation	  of	  nascent	  HDL.	  The	  effect	  of	  the	  lack	  of	  expression	  of	  
ABCA1	   and	   the	   development	   of	   atherosclerosis	   has	   shown	   some	   contradicting	  
results.	   On	   an	   atherosclerotis	   prone	   knockout	   background,	   namely	   the	   apoE	  
knockout,	  liver	  specific	  deletion	  of	  ABCA1	  has	  led	  to	  an	  increased	  development	  of	  
atherosclerosis	   after	   12	   weeks	   of	   chow	   diet	   111.	   However,	   Bi	   et	   al.	   112	   have	  
demonstrated	   that	   when	   cross-­‐bred	   to	   an	   LDL	   receptor	   knockout	   background,	  
liver	   specific	   deletion	   of	   ABCA1	   did	   not	   affect	   the	   development	   of	   early	  
atherosclerosis	   after	   5	   weeks	   of	   Western	   diet	   feeding	   ,but,	   paradoxically,	   did	  
decrease	  atherosclerotic	  lesion	  after	  16	  weeks	  of	  Western	  diet.	  
Interestingly,	  when	  the	  cholesterol	  content	  in	  the	  aortas	  of	  both	  animal	  models,	  is	  
plotted	  against	  the	  effect	  on	  lesion	  development	  113,	  it	  is	  clear	  that	  hepatic	  ABCA1	  
deletion	   is	   more	   atheroprotective	   when	   the	   accumulation	   of	   cholesterol	   in	   the	  
aorta	  is	  higher,	  thus	  lesions	  are	  larger	  and	  likely	  more	  advanced.	  The	  macrophage	  
to	  feces	  reverse	  cholesterol	  transport	  was	  tested	  on	  these	  mice	  by	  the	  injection	  of	  
3H	  cholesterol	  loaded	  macrophages	  in	  the	  peritoneum	  and	  recovered	  in	  the	  liver,	  
and	   has	   shown	   to	   not	   be	   affected	   by	   the	   knockout	   112.	   This	   suggests	   that	   the	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reduced	  plasma	  pools	   of	  HDL	  or	   other	   factors,	   such	   as	   albumin,	   erythrocytes	   or	  
apoB	   lipoproteins,	   are	   sufficient	   to	  maintain	   reverse	   cholesterol	   transport.	   Liver	  
specific	  deletion	  of	  ABCA1	  also	  led	  to	  1.5	  fold	  decrease	  in	  apoB	  lipoprotein	  levels,	  
both	  in	  apoE	  and	  in	  the	  LDL	  receptor	  knockout	  mice.	  This	  reduced	  level	  might	  be	  
partially	   explained	   by	   an	   observed	   enhanced	   clearance	   of	   apoB	   lipoproteins.	  
Notably,	   macrophage-­‐specific,	   bone	   marrow-­‐specific	   and	   intestine-­‐specific	  
deletion	  of	  ABCA1	  has	  been	  shown	  to	  reduce	  apoB	  lipoproteins.	  	  
Iqbal	   et	   al.	   114	   have	   shown	   that	   intestine	   ABCA1	   contributes	   for	   approximately	  
28%	  of	  dietary	  cholesterol	  absorption.	  In	  line,	  using	  an	  in	  situ	  intestine	  perfusion	  
model,	  it	  was	  recently	  demonstrated	  that	  the	  intestine	  produces	  HDL	  by	  a	  process	  
that	   involves	   ABCA1	   115.	   HDL	   particles	   produced	   by	   the	   intestine	   are	   spherical,	  
enriched	  in	  triglycerides	  and	  contain	  additional	  major	  peptides	  compared	  to	  HDL	  
produced	  in	  the	  liver.	  The	  intestine	  specific	  ABCA1	  expression	  also	  leads	  to	  20%	  
reduced	  HDL	  cholesterol	  level	  in	  the	  plasma	  116	  
4.3.1.3. ABCA1	  effect	  in	  the	  arterial	  wall	  
In	   the	   arterial	   wall,	   ABCA1	   is	   expressed	   by	   endothelial	   cells,	   macrophages,	   and	  
smooth	   muscle	   cells.	   ABCA1	   has	   been	   extensively	   studied	   in	   macrophages.	  
Evidence	   is	   emerging	   that	   endothelial	   ABCA1	   has	   an	   important	   role	   in	  
atherosclerosis	  development	  as	  well.	  It	  has	  been	  shown	  that	  ABCA1	  expression	  is	  
approximately	  3	  fold	  upregulated	  in	  aortic	  endothelial	  cells	  of	  apoE	  knockout	  mice	  
117	  compared	  to	  wild	  type	  controls.	  Endothelial	  ABCA1	  has	  been	  shown	  to	  protect	  
against	   atherosclerosis	   by	   preserving	   endothelium	   dependent	   vasorelaxation	   69	  
and	  facilitating	  transcytosis	  of	  apoA-­‐I	   into	  the	  arterial	  wall	  118.	  Recent	  studies	  119	  
have	  demonstrated	  that	  under	  atheroprotective	  high	  shear	  stress	  conditions	  nitric	  
oxide	   release	   by	   endothelial	   cells	   downregulates	   ABCA1	   expression.	   Under	  
atherosclerosis	   prone	   low	   shear	   stress	   conditions,	   endothelial	   nitric	   oxide	  
synthase	  expression	  is	  downregulated	  leading	  to	  reduced	  nitric	  oxide	  production.	  	  
Variable	   effects	   of	   overexpression	   of	   human	   endothelial	   ABCA1	   expression	   on	  
atherosclerotic	  lesion	  development	  have	  been	  observed.	  No	  significant	  differences	  
in	  atherosclerosis	  were	  found	  on	  mice	  overexpressing	  ABCA1	  in	  the	  endothelium	  
under	   the	   control	   of	   the	   Tie	   2	   promoter	   on	   an	   apoE	   knockout	   background	   120.	  
However,	   in	   wild	   type	   mice	   challenged	   with	   Western	   diet	   for	   four	   months,	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atherosclerotic	   lesions	   were	   reduced	   in	   mice	   overexpressing	   ABCA1	   in	   the	  
endothelium.	  	  
The	  role	  of	  ABCA1	  in	  macrophages	  and	  other	  bone	  marrow	  derived	  cells	  has	  been	  
studied	  by	  transplantation	  of	  bone	  marrow	  of	  total	  ABCA1	  knockout	  mice	  into	  LDL	  
receptor	  knockout	  animals.	  The	  results	  of	  these	  studies	  showed	  that	  the	  absence	  
of	   ABCA1	   expression	   in	   bone	   marrow	   derived	   cells	   increases	   atherosclerosis	  
development	  101.	  These	  observations	  seemed	  to	  be	  attributed	  to	  macrophages.	  As	  
another	  study	  showed,	  myeloid-­‐specific	  ABCA1	  knockout	  mice	  did	  not	  result	  in	  an	  
increased	  in	  atherosclerosis	  susceptibility	  111.	  
Smooth	   muscle	   cells	   in	   the	   intima	   can	   accumulate,	   similarly	   to	   macrophages,	  
cholesterol	   and	   differentiate	   into	   lipid	   laden	   foam	   cells.	   Recent	   studies	   using	  
human	  coronary	  artery	  sections	  showed	  that	  ABCA1	  expression	  in	  smooth	  muscle	  
cells	  was	  downregulated	  during	   lesion	  progression,	  but	  this	  was	  not	  the	  case	  for	  
macrophages	  121.	  These	  observations	  can	  explain	  why	  at	  least	  50%	  of	  foam	  cells	  in	  
human	  atherosclerotic	  lesion	  are	  from	  smooth	  muscle	  cell	  origin.	  
ABCA1-­‐mediated	   efflux	   is	   determined	   by	   ABCA1	   expression,	   but	   also	   by	   the	  
availability	  of	  cholesterol	  acceptors.	  As	  previously	  mentioned,	  apoA-­‐I	  is	  produced	  
in	  the	  liver,	  therefore,	  its	  availability	  in	  the	  arterial	  wall	  is	  mediated	  by	  infiltration	  
from	   the	   circulation.	  DiDonato	   JA,	  Huang	  Y,	   Aulak	  KS,	   et	   al.	   122	   have	   shown	   that	  
lipid-­‐poor	  apoA-­‐I	  is	  predominantly	  accumulating	  in	  atherosclerotic	  plaque.	  Recent	  
studies	   by	   the	   same	   group	   123,	   have	   demonstrated	   that	   the	   lipid-­‐poor	   apoA-­‐I	   is	  
highly	   oxidized	   by	   myeloperoxidase	   produced	   by	   granulocytes	   at	   the	  
atherosclerotic	   lesion	   site.	   	   This	   oxidized	   apoA-­‐I	   had	   an	   impaired	   ABCA1	  








4.3.2. ATP	  binding	  Cassette	  G1	  
ABCG1	   is	   another	  member	   of	   the	   large	   ATP-­‐binding	   cassette	   transporter	   family	  
and	   belongs	   to	   the	   G	   subfamily,	   which	   contains	   five	   characterized	   transporters:	  
ABCG1,	  ABCG2,	  ABCG4,	  ABCG5,	  and	  ABCG8.	  ABCG	  proteins	  are	  half-­‐transporters,	  
composed	  of	  an	  intracellular	  amino-­‐terminal	  nucleotide-­‐binding	  domain	  followed	  
by	   the	   carboxy-­‐terminal	   domain	   containing	   six	   transmembrane	   α-­‐helices	   124.	  
ABCG1	   is	  predominantly	  expressed	   in	  hepatocytes,	  but	  can	  also	  be	  expressed	  by	  
other	  cell	  types.	  
In	  contrast	  to	  ABCA1,	  ABCG1	  mediates	  cholesterol	  efflux	  to	  HDL	  particles,	  but	  not	  
to	   lipid-­‐free	   apoA-­‐I	   125,126.	   ABCG1	   knockout	  mice	   showed	   defective	  macrophage	  
cholesterol	   efflux	   to	   HDL	   and	   when	   challenged	   with	   a	   high-­‐fat	   diet,	   developed	  
prominent	  macrophage	   foam	   cells	   accumulation	   in	   the	   lung	   125.	  However,	   these	  
mice	  did	  not	  exhibit	  alterations	   in	  plasma	   lipoprotein	   levels.	  Macrophage	  ABCG1	  
seems	  to	  contribute	  to	  macrophage	  reverse	  cholesterol	  transport,	  supporting	  an	  in	  
vivo	  role	  of	  ABCG1	  in	  macrophage	  cholesterol	  efflux	  and	  transport	  via	  the	  plasma	  
compartment	   to	   the	   liver	   and	   feces	   127.	   The	   role	   of	   hematopoietic	   ABCG1	   in	  
atherosclerosis	  has	  presented	  conflicting	  results.	  One	  study	  has	  shown	  increased	  
atherosclerosis	   in	   mice	   transplanted	   with	   ABCG1	   knockout	   bone	   marrow	   128,	  
whereas	   two	   independent	  studies	  have	  shown	  the	  contradictory	  results	  129,130.	  A	  
possible	   explanation	   of	   this	   discrepancy	   might	   be	   different	   effects	   of	   various	  











4.3.3. Scavenger	  Receptor	  B1	  
SR-­‐BI	   is	   an	   82-­‐kDa	  membrane	   glycoprotein	   containing	   a	   large	   extracellular	   and	  
two	   trans-­‐membrane	   domains	   with	   a	   short	   cytoplasmic	   amino-­‐	   and	   carboxyl-­‐
terminal	   domain	   132.	   SR-­‐BI	   is	  mainly	   found	   in	   the	   liver,	   but	   is	   also	   expressed	   in	  
other	   tissues	   and	   cells	   types,	   such	   as	   macrophages	   and	   endothelial	   cells.	   SR-­‐BI	  
mediates	  the	  selective	  uptake	  of	  HDL	  cholesteryl	  esters	  to	  the	   liver	   for	  excretion	  
into	   the	   bile	   133.	   The	   selective	   uptake	   involves	   the	   transfer	   to	   the	   cell	   of	   the	  
cholesteryl	   esters	   from	   the	   lipoprotein’s	   hydrophobic	   core,	   but	   not	   the	  
apolipoprotein	   at	   the	   lipoprotein’s	   surface.	   It	   does	   not	   involve	   the	   sequential	  
internalization	   of	   the	   intact	   lipoprotein	   particle	   and	   its	   subsequent	   degradation	  
132.	  In	  vivo	  studies	  have	  indicated	  that	  half	  normal	  levels	  of	  hepatic	  SR-­‐BI	  protein	  
in	   mice	   were	   associated	   with	   50%	   reduction	   in	   selective	   delivery	   of	   HDL	  
cholesteryl	  esters	  to	  the	  liver	  134.	  Furthermore,	  selective	  uptake	  of	  HDL-­‐associated	  
cholesteryl	   esters	   by	   the	   liver	  was	   almost	   completely	   absent	   in	   SR-­‐BI	   knockout	  
mice	   135.	   	   As	   a	   consequence	   of	   reduced	   selective	   uptake	   of	   HDL-­‐associated	  
cholesteryl	   esters,	   HDL	   plasma	   concentration	   and	   overall	   particle	   size	   are	  
increased	  in	  SR-­‐BI	  knockout	  mice	  136.	  Acute	  adenovirus-­‐mediated	  overexpression	  
of	  SR-­‐BI	  in	  the	  liver	  of	  mice	  resulted	  in	  almost	  complete	  catabolism	  of	  HDL	  137.	  
On	  another	  note,	  the	  absence	  of	  SR-­‐BI,	   in	  apoE	  knockout	  mice	  or	  LDLR	  knockout	  
fed	  a	  high-­‐fat	  diet,	  shows	  increased	  atherosclerosis	  138,139,	  whereas	  atherosclerosis	  












4.4. Transport	  of	  HDL	  through	  the	  endothelium	  
In	  general	  the	  transport	  of	  molecules	  through	  endothelial	  or	  epithelial	  barriers	  is	  
determined	   by	   their	   water	   solubility,	   size	   and	   charge.	   However,	   systematic	  
permeability	   studies	   in	   endothelial	   monolayers	   revealed	   that	   this	   correlation	   is	  
valid	  only	  for	  water	  soluble	  molecules	  with	  a	  diameter	  below	  6	  nm.	  The	  transport	  
of	  larger	  molecules	  is	  much	  slower	  and	  does	  not	  show	  any	  correlation	  with	  size142	  
143.	  Thus,	   the	   transendothelial	   transport	  of	  HDL	  ranging	   in	  diameters	  between	  8	  
nm	  and	  15	  nm	  requires	  special	  prerequisites.	   In	   fact	  morphological,	  biochemical	  
and	   physiological	   studies	   have	   provided	   strong	   evidence	   that	   proteins	   pass	   the	  
intact	   endothelium	   by	   both	   paracellular	   and	   transcellular	   routes,	   which	   involve	  
the	   regulated	   opening	   and	   closure	   of	   interendothelial	   junctions,	   and	   vesicular	  
pathways,	  respectively	  144.	  	  
Our	  group	  has	  previously	  shown	  by	  both	  biochemical	  and	  microscopic	  studies	  that	  
cultivated	   bovine	   aortic	   endothelial	   cells	   bind,	   internalize	   and	   transcytose	   both	  
apoA-­‐I	   and	   HDL	   in	   a	   saturable	   and	   temperature-­‐dependent	   manner	   145.	   Similar	  
data	   were	   obtained	   in	   human	   aortic	   endothelial	   cells	   (HAEC),	   human	   umbilical	  
venous	   endothelial	   cells	   (HUVECs),	   bovine	   microvascular	   endothelial	   cells	  
(BMEC),	  as	  well	  as	  the	  human	  endothelial	  cell	  line	  EA.hy926	  (146	  and	  unpublished).	  
By	   using	   RNA	   interference	   and	   apoA-­‐I	   mutants,	   we	   demonstrated	   that	  
transendothelial	   transport	  of	   lipid-­‐free	  apoA-­‐I	   requires	  ABCA1	   118	   and	   the	   intact	  
carboxylterminus	   of	   wild-­‐type	   apoA-­‐I91,	   thus	   underlining	   the	   specificity	   of	   the	  
transendothelial	   apoA-­‐I	   transport.	   RNA	   interference	   with	   ABCG1,	   SR-­‐BI,	   EL,	   or	  
ectopic	   beta-­‐ATPase	   compromised	   the	   transendothelial	   transport	   of	   intact	   HDL	  
particles	  146–148.	  
In	   addition,	  we	   showed	   that	   the	   transendothelial	   apoA-­‐I	   transport	   is	   a	   two-­‐step	  
process	  in	  which	  apoA-­‐I	  is	  initially	  lipidated	  by	  ABCA1	  and	  then	  further	  processed	  
by	   mechanisms	   that	   are	   independent	   of	   ABCA1,	   but	   involve	   ABCG1,	   SR-­‐BI,	   and	  
EL91,146,147,149.	   Thus,	   after	   lipidation,	   initially	   lipid-­‐free	   apoA-­‐I	   and	   mature	   HDL	  
particles	   are	   trafficked	   through	   the	   same	  pathway	   through	   endothelial	   cells.	  We	  
found	  biochemical	  evidence	  that	  apoA-­‐I	  stimulates	  the	  transport	  of	  initially	  lipid-­‐
free	  apoA-­‐I	  and	  HDL	  across	  endothelial	  cells	  by	  inducing	  ectopic	  cell	  surface	  F0F1-­‐
ATPase	   to	   generate	   extracellular	   ADP.	   The	   ADP	   then	   activates	   the	   purinergic	  
receptor	  P2Y12	  to	  stimulate	  the	  endocytosis	  of	  HDL	  or	  lipidated	  apoA-­‐I	  148.	  	  These	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findings,	   summarized	   in	  Figure	   5,	   suggest	   that	  endothelial	  ABCA1	  plays	  a	  major	  
role	  in	  apoA-­‐I	  transport	  through	  endothelial	  cells	  in	  vitro.	  	  
	  
Figure	   5	   -­‐	   Current	   working	   model	   of	   transendothelial	   apoA-­‐I	   and	   HDL	   transport.	   By	  
lipidating	   ApoA-­‐I	   ABCA1	   generates	   a	   particle	   that	   is	   processed	   by	   a	  mechanism	  which,	   like	   the	  
transport	  of	  mature	  HDL,	  involves	  ABCG1	  and	  SR-­‐BI.	  Upon	  binding	  of	  ApoA-­‐I	  ectopic	  F0F1	  ATPase	  
in	   the	   plasma	  membrane	   hydrolyzes	   ATP.	   The	   produced	  ADP	   binds	   to	   P2Y12	   and	   stimulates	   the	  
internalization	  and	  transendothelial	  transport.	  Adapted	  from	  148.	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5. Aim	  of	  the	  Study	  
During	  their	  metabolism,	  lipoproteins,	  including	  HDL,	  pass	  endothelial	  barriers	  at	  
several	  occasions,	  namely	  1)	  after	  secretion	   from	  the	   liver	  and	   intestine	   into	   the	  
blood	   and	   lymph,	   respectively,	   2)	   from	   the	   blood	   into	   extravascular	  
compartments,	  where	  they	  exert	  their	  (patho)physiological	  functions,	  3)	  from	  the	  
extravascular	   compartments	   back	   into	   the	   circulation,	   and	   finally,	   4)	   from	   the	  
circulation	  into	  the	  catabolic	  organs.	  HDL	  must	  also	  pass	  the	  endothelial	  barrier	  of	  
arteries	   to	   exert	   their	   anti-­‐atherosclerotic	   properties;	   for	   example,	   to	   induce	  
cholesterol	   efflux	   from	   lipid	   laden	  macrophages.	   Even	  more	   so,	   to	   continue	   the	  
reverse	  transport	  of	  cholesterol	  from	  these	  foam	  cells	  in	  the	  arterial	  intima	  to	  the	  
liver,	  HDL	  must	   again	   leave	   the	   arterial	  wall,	   probably	   via	   vasa	   vasorum,	  which	  
have	   grown	   into	   the	   thickened	   intima.	   It	   hence	   crosses	   an	   endothelial	   barrier	   a	  
second	  time,	  this	  time	  from	  basolateral-­‐to-­‐apical.	  
Our	   group	   has	   previously	   shown	   that	   the	   transendothelial	   transport	   of	   apoA-­‐I	  
requires	  a	   lipidation	  process	   that	   involves	  ABCA1.	  After	   lipidation,	   initially	   lipid-­‐
free	  apoA-­‐I	  and	  mature	  HDL	  particles	  are	  trafficked	  by	  the	  same	  pathway	  through	  
endothelial	   cells,	   involving	   SR-­‐BI	   and	   ABCG1.	   These	   findings	   suggest	   that	  
endothelial	   ABCA1	   plays	   a	   major	   role	   in	   apoA-­‐I	   transport	   through	   endothelial	  
cells.	  	  
The	  aim	  of	  this	  thesis	  is	  to	  investigate	  the	  physiological	  and	  pathological	  relevance	  
of	  endothelial	  ABCA1,	  as	  well	  as	  for	  apoA-­‐I	  and	  HDL	  transport	  in	  vivo,	  using	  mice	  
with	  a	  targeted	  knockout	  of	  ABCA1	  in	  endothelial	  cells	  (Abca1e-­‐/-­‐).	  We	  specifically	  
addressed	  the	  following	  questions:	  
-­‐ How	   does	   the	   absence	   of	   endothelial	   ABCA1	   affect	   the	   metabolism	   and	  
extravascular	  accumulation	  of	  apoA-­‐I	  and	  HDL?	  
-­‐ What	  role	  does	  ABCA1	  have	  in	  the	  microvasculature?	  
-­‐ Does	   the	   absence	   of	   endothelial	   ABCA1	   affect	   the	   endothelial	   dependent	  
vasorelaxation	  of	  aortic	  rings?	  
-­‐ How	   does	   endothelial	   ABCA1	   affect	   atherosclerosis	   development?	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6. Material	  and	  Methods	  
6.1. Generation	  of	  endothelial	  specific	  ABCA1	  knockout	  mouse	  
The	  endothelial	  specific	  knockout	  mice	  were	  provided	  by	  Professor	  John	  S.	  Parks	  
from	   Wake	   Forest	   University.	   His	   group	   generated	   the	   floxed	   ABCA1	   mice	   as	  
previously	   described	   110.	   Briefly,	   a	   duplication/deletion	   targeting	   vector	  
(Osdupdel;	   courtesy	  of	  Oliver	  Smithies,	  University	  of	  North	  Carolina,	  Chapel	  Hill,	  
North	  Carolina,	  USA)	  was	  used	  to	  generate	  the	  targeting	  construct.	  The	  short	  and	  
long	  arms	  of	  the	  targeting	  construct	  were	  derived	  from	  a	  6.4-­‐kb	  BamHI	  fragment	  
that	   was	   detected	   by	   screening	   a	   129/SvEv	   genomic	   DNA	   λ	   phage	   library	  
(provided	   by	   Hyung-­‐Suk	   Kim,	   University	   of	   North	   Carolina,	   Chapel	   Hill,	   North	  
Carolina,	   USA)	   with	   a	   PCR-­‐generated	   probe	   spanning	   intron	   44.	   The	   short	   arm	  
consisted	  of	  a	  1.2-­‐kb	  BglII	  fragment	  from	  intron	  44,	  and	  the	  long	  arm	  consisted	  of	  
a	  4.3-­‐kb	  region	   from	  the	  downstream	  BglII	  site	  of	   intron	  44	  to	   the	  EcoRV	  site	   in	  
intron	  49.	  A	  loxP	  site,	  in	  addition	  to	  the	  2	  flanking	  the	  neomycin	  resistance	  gene,	  
was	  introduced	  into	  the	  targeting	  vector	  at	  the	  HindIII	  site	  in	  intron	  46,	  such	  that	  
exons	  45–46,	  which	  encode	   the	   second	  nucleotide-­‐binding	   fold,	  were	   flanked	  by	  
loxP	  sites	   (Figure	   6).	  The	   targeting	  construct	  was	  electroporated	   into	  129/SvEv	  
Tac	   embryonic	   stem	   cells,	   which	   were	   then	   subjected	   to	   positive	   and	   negative	  
selection	  for	  homologous	  recombination	  with	  G418	  and	  ganciclovir,	  respectively.	  
Surviving	  embryonic	  stem	  cells	  were	  screened	  by	  PCR	  and	  Southern	  blot	  analysis,	  
and	  correctly	  targeted	  cells	  were	  expanded	  and	  injected	  into	  C57BL/6	  (B6)	  mouse	  
blastocysts	  and	  implanted	  into	  pseudopregnant	  B6	  female	  mice.	  The	  agouti	  male	  
mice	   were	   bred	   to	   B6	   female	   mice	   to	   test	   for	   germline	   transmission	   of	   the	  
conditionally	  targeted	  allele	  (i.e.,	  floxed	  allele).	  They	  then	  made	  sibling	  crosses	  to	  
generate	   Abca1flox/flox	  mice	   and	   bred	   these	  mice	  with	   B6	  mice	   expressing	   the	  
Cre	   transgene	   under	   control	   of	   the	   VE-­‐cadherin	   promoter	   150	   (B6.Cg-­‐Tg(Cdh5-­‐
cre)7Mlia/J,	   Jackson	  ImmunoResearch	  Laboratories).	  VE-­‐Cadherin	  (control	  mice)	  
and	   ABCA1	   floxed,	   VE-­‐Cadherin-­‐Cre	   positive	   (ABCA1e-­‐/-­‐)	   littermates	   at	   three	  
months	  of	  age	  were	  used	   in	   the	  experiments	  unless	  stated	  otherwise.	  Mice	  were	  
housed	  under	  12	  h	  light/dark	  cycles	  and	  received	  a	  standard	  laboratory	  chow	  diet	  
or	   high	   fat	   and	   high	   cholesterol	   diet	   with	   1.25%	   cholesterol	   (Research	   diet,	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D12108C).	   All	   animal	   procedures	   were	   approved	   by	   the	   Zurich	   Cantonal	  
Veterinary	  Office.	  
	  
Figure	   6	   -­‐	   Schematic	   of	   3’	   region	   (exons	   44–49)	   of	   Abca1	   gene	   showing	   wild-­‐type	   (top),	  
floxed	   (middle),	   and	   knockout	   (bottom)	   Abca1	   alleles.	   Three	   loxP	   sites,	   2	   flanking	   the	  
neomycin	  (Neo)	  resistance	  gene	  and	  1	  in	   intron	  46,	  are	  shown	  as	  arrowheads.	  Arrows	  the	  floxed	  
allele	  indicate	  relative	  position	  of	  primers	  used	  for	  PCR	  screen	  of	  alleles.	  The	  size	  of	  the	  EcoRV	  (RV)	  
fragment	  is	  shown	  above	  each	  allele,	  and	  the	  relative	  location	  of	  the	  probe	  used	  for	  Southern	  blot	  
analysis	   is	  shown	  above	  the	  wild-­‐type	  allele	  (Probe	  A).	  Cre	  recombinase–mediated	  elimination	  of	  
exons	   45	   and	   46	   will	   delete	   the	   second	   ATP-­‐binding	   cassette,	   resulting	   in	   a	   knockout	   allele.	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6.2. Genotyping	  
Tissue	   biopsies	   were	   obtained	   by	   ear	   punches,	   DNA	   was	   extracted	   using	  
REDExtract-­‐N-­‐Amp™	  Tissue	  PCR	  Kit	  (Sigma).	  The	  following	  primers	  were	  used	  to	  
determine	   the	   inheritance	   of	   the	   Cre	   transgene	   and	   Abca1	   alleles:	   VE-­‐Cad	   Cre	  
Forward	  GCA	  GGC	  AGC	  TCA	  CAA	  AGG	  AAC	  AA	  VE-­‐Cad	  Gene	  Reverse	  TGT	  CCT	  TGC	  
TGA	  GTG	  ACA	  GTG	  GAA	  and	  VE-­‐Cad	  Cre	  Reverse	  ATC	  ACT	  CGT	  TGC	  ATC	  GAC	  CGG	  
TAA,	  ABCA1	  Forward	  GGA	  GGT	  GAC	  TGA	  AAG	  GCA	  TCC	  ATC	  and	  reverse	  CCT	  GTC	  
TCA	  GCC	  CTG	  CAT	  GC.	  
The	   inheritance	  of	   the	  LDL	   receptor	   gene	  knockout	  was	  determined	  using	   these	  
primers:	   common	   primer:	   AAT	   CCA	   TCT	   TGT	   TCA	   ATG	   GCC	   GAT	   C,	   Wild	   type	  
reverse:	   CTA	  CCC	  AAC	  CAG	  CCC	  CTT	  AC	   and	  mutant	   reverse	  ATA	  GAT	  TCG	  CCC	  
TTG	  TGT	  CC.	  
6.3. Immunofluorescence	  microscopy	  of	  ABCA1	  and	  endothelial	  markers	  
Mouse	   tissue	   (aorta,	   liver,	   lung,	   kidney	   or	   back	   skin)	   cryosections	   of	   7	   µm	  
thickness	  were	  fixed	  with	  acetone	  (–20ºC),	  dehydrated	  with	  80%	  methanol	  (4ºC)	  
and	   were	   incubated	   overnight	   with	   a	   rabbit	   anti-­‐ABCA1	   antibody	   (Novus,	   Cat	  
no:400-­‐105,	   1:100),	   a	   rat	   anti-­‐mouse	   CD31	   antibody	   (BD	   Pharmingen,	   Cat	   no:	  
550274,	   1:100)	   and,	   when	   mentioned,	   a	   biotinylated	   goat	   anti-­‐mouse	   LYVE-­‐1	  
antibody	   (R&D,	   Cat	   no:BAF2125,	   1:100).	   AlexaFluor	   488-­‐,	   594-­‐	   and	   647-­‐	  
conjugated	   secondary	   antibodies	   (Molecular	   Probes)	   and	   Hoechst	   33342	  
(Invitrogen)	   were	   used	   for	   the	   detection	   and	   the	   images	   were	   acquired	   with	   a	  
confocal	  microscope	  (CLSM,	  SP5	  Leica).	  	  
6.4. Whole	  mount	  immunostainings	  
Whole	  mount	  immunostainings	  were	  performed	  as	  described	  151.	  Briefly,	  left	  ears	  
were	   split	   and	   the	   inner	   part	   of	   the	   ear	   was	   used	   for	   analyses.	   Aortae	   were	  
dissected	   and	   the	   brachiocephalic	   branches	   were	   marked	   by	   placing	   a	   7-­‐0	   silk	  
suture	   for	   reference.	   Primary	   antibodies	   used	   were:	   rabbit-­‐anti-­‐mouse	   LYVE-­‐1	  
(AngioBio,	  Cat	  no:	  11-­‐034,	  1:600	  dilution),	  rat-­‐anti-­‐mouse	  CD31	  (BD	  Pharmingen,	  
Cat	   no:	   550274,	   1:200),	   mouse-­‐anti-­‐α-­‐SMA	   (Sigma,	   Cat	   no:	   C6198-­‐2ML,	   1:1000,	  
Cy3	  conjugated).	  AlexaFluor	  488-­‐,	  594-­‐	  and	  647-­‐	  conjugated	  secondary	  antibodies	  
(1:200	  dilution)	  were	  purchased	   from	  Molecular	  Probes.	  The	   samples	  were	   flat-­‐
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mounted	   on	   glass	   slides	   in	  Mowiol	   (Calbiochem).	   	   For	   the	   ears,	  wide-­‐field	   (12x,	  
whole	   ear)	   or	   close-­‐up	   (34x,	   rim	   of	   the	   ear)	   images	   were	   acquired	   with	   an	  
AxioZoom.V16	   stereo	   zoom	   microscope	   (Carl	   Zeiss)	   fitted	   with	   a	   QImaging	  
OptiMOSTM	  sCMOS	  camera	  (CoolLED	  Ltd).	  Zen	  pro	  software	  (Carl	  Zeiss)	  was	  used	  
with	   a	   Cy5	   filter	   set	   at	   500	   ms	   and	   400	   ms	   exposure	   times,	   respectively.	   The	  
acquired	   images	  were	   processed	   using	   ImageJ	   (Version	   2.0.0-­‐rc-­‐23/1.49m,	  NIH)	  
and	  Adobe	  Photoshop	  CS5	  (Adobe	  Systems).	  Areas	  covered	  by	  lymphatic	  vessels,	  
determined	  by	  LYVE-­‐1	  staining,	  were	  analyzed	  with	  a	  self-­‐prepared	  pipeline	  using	  
CellProfiler	  software	  (version	  2.1.0,	  BROAD	  Institute).	  Vessel	  length	  was	  measured	  
in	   ImageJ	   and	   the	  number	   of	   branch	  points	  was	   counted	  manually.	   The	   average	  
lymphatic	  vessel	  diameter	  was	  calculated	  by	  dividing	  LYVE-­‐1+	  area	  by	  total	  vessel	  
length.	  Z-­‐stack	  images	  of	  aorta	  preparations	  were	  acquired	  with	  a	  Zeiss	  LSM	  710-­‐
FCS	   confocal	   microscope	   (Carl	   Zeiss)	   equipped	   with	   a	   20×	   0.8	   NA	   Plan-­‐
Apochromat	   objective	   (Carl	   Zeiss)	   using	   the	   Zeiss	   ZEN	   2009	   software	   and	  
processed	  using	  ImageJ	  (NIH).	  
6.5. Western	  blot	  analysis	  and	  PCR	  
Approximately	   one	   gram	   of	   tissue	   (liver,	   spleen,	   kidney,	   lung	   or	   brain)	   was	  
washed	   in	   cold	   PBS	   and	   fast	   frozen	   with	   liquid	   nitrogen.	   The	   tissue	   was	   then	  
grinded	  with	   a	  mortar	   and	   pestle.	   The	   powdered	   tissue	  was	   then	   homogenized	  
with	   lysis	   buffer	   and	   complete	   protease	   inhibitor	   (Roche	   Diagnostics	   Corp.).	  
Protein	   concentration	   was	   determined	   by	   the	   DC	   protein	   assay	   (Bio	   Rad).	  
Equivalent	  amounts	  of	   total	  protein	  were	  separated	  by	  SDS-­‐PAGE,	   transferred	  to	  
PVDF	   membranes,	   and	   probed	   with	   anti-­‐ABCA1	   (Novus)	   or	   anti-­‐actin	   (Sigma)	  
antibodies.	   Abca1	   expression	   on	   the	   RNA	   level	   was	   tested	   using	   the	   following	  
primers	  for	  PCR	  for	  Abca1	  were:	  forward	  CGTTTCCGGGAAGTGTCCTA	  and	  reverse	  
GATGACAAGGAGGATGGA.	   And	   for	   GAPDH:	   forward	   AAGCTGTGGCGTGATGGCCG	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6.6. Bone	  marrow	  derived	  macrophages	  (BMDM)	  isolation	  
BMDM	   were	   isolated	   as	   described	   152.	   Briefly,	   mice	   were	   sacrificed	   by	   CO2	  
overdose,	  skin	  was	  removed	  and	  legs	  were	  cut.	  After	  removing	  all	  muscle	  tissues	  
with	   gauze	   from	   the	   femurs	   and	   tibias,	   both	   ends	   of	   the	   bones	   were	   cut	   with	  
scissors	  in	  a	  dish,	  and	  then	  the	  marrow	  was	  flushed	  out	  using	  2	  ml	  of	  Phosphate	  
buffered	   saline	  with	   a	   syringe	   and	   25	   gauge	   needle.	   The	   tissue	  was	   suspended,	  
passed	   through	  nylon	  mesh	   to	   remove	   small	   pieces	  of	   bone	   and	  debris,	   and	   red	  
cells	  were	  lysed	  with	  ammonium	  chloride.	  0.8	  to	  1	  x	  106	  cells	  were	  placed	  in	  6	  well	  
plates	   in	   3	   ml	   of	   medium	   supplemented	   with	   500-­‐1,000	   U/ml	   GM-­‐CSF.	   The	  
cultures	  were	  usually	  fed	  every	  two	  days	  by	  gently	  swirling	  the	  plates,	  aspirating	  
75%	  of	  the	  medium,	  and	  adding	  back	  fresh	  medium	  with	  GM-­‐CSF.	  This	  procedure	  
ensured	  to	  remove	  non-­‐adherent	  granulocytes	  from	  firmly	  adherent	  macrophages.	  
After	   seven	   days,	   cells	   were	   ready	   for	   experiment.	   The	   BMDM	   were	   then	  
stimulated	  with	  10	  µM	  of	  LXR	  agonist	  T0901317	   for	  20	  hours	   to	   control	  ABCA1	  
expression.	  	  
6.7. Lipid	  and	  lipoprotein	  analysis	  
Plasma	   lipid	   concentrations	   were	   determined	   in	   mice	   fasted	   for	   four	   hours.	  
Cholesterol	  and	  triglyceride	  concentrations	  were	  determined	  by	  enzymatic	  assays	  
using	   commercially	   available	   reagents	   (Life	   Technologies).	   Lipoprotein	   profiles	  
were	   determined	   by	   fast	   protein	   liquid	   chromatography	   (FPLC)	   using	   two	  
Superose-­‐6	  FPLC	  columns	  in	  series	  (HR10/30)	  in	  PBS	  with	  0.1	  mM	  EDTA,	  pH	  7.5	  
at	   0.5	   ml/min.	   Columns	   were	   calibrated	   using	   high	   and	   low	   molecular	   weight	  
standards	   (Pharmacia,	   Stockholm,	   Sweden).	   500	   µl	   of	   serum	  was	   loaded	   on	   the	  
column,	  the	  first	  10	  ml	  were	  discarded	  and	  afterwards	  70	  samples	  of	  500	  µl	  were	  
collected	   for	   analysis.	   Cholesterol	   and	   phospholipid	   concentrations	   were	  
measured	   using	   colorimetric	   and	   enzymatic	   methods	   with	   ready	   to	   use	   kits	  
(Amplex	   red	   cholesterol	   kit,	   Life	   Technologies	   and	   EnzyChromTM	   Phospholipid	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6.8. Glucose	  tolerance	  test	  (GTT)	  and	  Insulin	  tolerance	  tests	  (ITT)	  
GTT	  and	  ITT	  were	  done	  on	  20-­‐week	  old	  mice	  that	  were	  fed	  a	  chow	  diet	  of	  a	  HFHC	  
diet	   for	   16	   weeks.	   Briefly,	   for	   GTT,	   mice	   were	   fasted	   overnight	   before	  
intraperitoneal	   (i.p.)	   injection	   of	   2g	   glucose/kg	   body	   weight	   (BW).	   Blood	   was	  
collected	  before	  and	  after	  injection	  (0,	  15,	  30,	  60,	  and	  120	  min)	  to	  measure	  glucose	  
concentrations	   using	   a	   commercial	   glucose	   monitor.	   One	   week	   later,	   the	   same	  
groups	  of	  mice	  were	  used	   for	   i.p.	   injection	  of	  1.5	  U	  of	   regular	  human	   insulin/kg	  
BW	  after	  a	  5h	  fast.	  Blood	  glucose	  concentrations	  were	  measured	  at	  0,	  15,	  30,	  60,	  
and	  120	  min	  after	  injection.	  Insulin	  was	  measured	  using	  an	  ELISA	  kit	  (Mercodia).	  
6.9. Isolation	  of	  lipoproteins	  and	  apoA-­‐I	  	  
HDL	  and	  LDL	  were	   isolated	   from	   fresh	  human	  normolipidemic	  plasmas	  of	  blood	  
donors	   by	   sequential	   ultracentrifugation	   153.	   The	   purity	   of	   the	   lipoprotein	  
preparation	  was	  verified	  by	  SDS-­‐PAGE	   in	  order	   to	  assure	  no	  contamination	  with	  
albumin.	   Acetylated	   LDL	   (acLDL)	   was	   prepared	   by	   addition	   of	   80	   μl	   of	   acetic	  
anhydride	  for	  5	  mg	  of	  LDL	  in	  50%	  ice-­‐cold	  saturated	  sodium	  acetate	  in	  portion	  of	  
10	  μl	   every	  15	  minutes	  at	  4°C.	  The	  acLDL	  was	   then	  extensively	  dialyzed	  against	  
0.15	  M	  NaCl,	  0.3	  mM	  EDTA,	  pH	  7.4.	  	  
Lipid-­‐free	  human	  plasma	  WT	  apoA-­‐I	  was	  extracted	  from	  delipidated	  HDL	  by	  FPLC	  
as	  described	  previously	  154.	  	  
6.10. Production	  and	  isolation	  of	  recombinant	  apoA-­‐I	  	  
ApoA-­‐I	  mutants	  were	  kindly	  provided	  by	  Professor	  Vassilis	  I.	  Zannis	  from	  Boston	  
University	   school	   of	  medicine.	  The	   generation	  of	   adenoviruses	   expressing	   apoA-­‐
I(L218A/L219A/V221A/L222A)	  was	  previously	  described	   155.	  Briefly,	   the	  apoA-­‐I	  
gene	  lacking	  the	  BglII	  restriction	  site	  (that	  is	  present	  at	  nucleotide	  positions	  181	  of	  
the	  genomic	  sequence	  relative	  to	  the	  ATG	  codon	  of	  the	  gene),	  was	  cloned	  into	  the	  
pCDNA3.1	   vector	   to	   generate	   the	   pCDNA3.1-­‐apoA-­‐I(ΔBglII)	   plasmid	   as	  
described156.	   This	   plasmid	   was	   used	   as	   a	   template	   to	   introduce	   the	   apoA-­‐
I(L218A/L219A/V221A/L222A)	   mutations	   in	   apoA-­‐I	   using	   the	   mutagenesis	   kit	  
QuickChange®	  XL	  (Stratagene)	  and	  the	  mutagenic	  primers.	  	  
The	  forward	  (F)	  and	  reverse	  (R)	  primers	  used	  are	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F:5’-­‐GGACCTCCGCCAAGGCGCGGCGCCCGCGGCGGAGAGC	  TTCAAGGTC-­‐3’and	  	  
R:5’-­‐GACCTTGAAGCTCTCCGCCGCGGGCGCCGCGCCTTG	  GCGGAGGTCC-­‐3’	  	  
Following	   18	   cycles	   of	   PCR	   amplification	   of	   the	   template	  DNA,	   the	   PCR	   product	  
was	   treated	  with	  DpnI	   to	   digest	   plasmids	   containing	  methylated	  DNA	   in	   one	   or	  
both	   of	   their	   strands.	   The	   reaction	   product,	   consisting	   of	   plasmids	   containing	  
newly	  synthesized	  DNA	  carrying	  the	  mutations	  of	  interest,	  were	  used	  to	  transform	  
competent	  XL-­‐10	  blue	  bacteria	  cells	  (Stratagene).	  Ampicillin-­‐resistant	  clones	  were	  
selected,	   and	   plasmid	   DNA	   was	   isolated	   from	   these	   clones	   and	   subjected	   to	  
sequencing	   to	   confirm	   the	   presence	   of	   the	   point	   mutations.	   The	   2.2	   kb	   apoA-­‐I	  
inserts	   containing	   the	  apoA-­‐I	  mutant	  was	   cloned	   into	   the	  pAdTrack	  CMV	  vector,	  
which	  was	  used	  to	  generate	  the	  adenoviral	  constructs	  by	  recombination	  with	  the	  
Ad-­‐Easy-­‐1	   helper	   virus	   in	   the	   bacteria	   cells	   BJ-­‐5183-­‐pAD1(Stratagene)	   that	  
contain	   the	   Ad-­‐Easy-­‐1	   helper	   virus.	   Correct	   clones	   were	   propagated	   in	   DH5a	  
bacteria	   cells.	   The	   recombinant	   adenoviral	   constructs	   were	   linearized	   after	  
incubation	   with	   PacI	   and	   used	   to	   transfect	   911	   cells.	   Following	   large-­‐scale	  
infection	   of	   human	   embryonic	   kidney	   293	   cell	   cultures,	   the	   recombinant	  
adenoviruses	   were	   purified	   by	   two	   consecutive	   CsCl	   ultracentrifugation	   steps,	  
dialyzed	  and	  titrated.	  The	  mutant	  protein	  was	  isolated	  from	  the	  culture	  medium	  of	  
HTB-­‐13	   cells	   infected	  with	   the	   apoA-­‐I(L218A/L219A/V221A/L222A)	   expressing	  
adenovirus	  as	  described157	  158.	  
6.11. Radiolabeling	  of	  proteins	  
Albumin,	  wild-­‐type	  and	  mutant	  apoA-­‐I	  were	  labeled	  with	  125I	  using	  the	  Iodination	  
Beads	   (Pierce)	   and	   Na125I	   (Hartmann	   Analytic)	   according	   to	   manufacturer's	  
instructions.	   In	   a	   typical	   reaction,	  we	  used	  0.5	  mCi	  of	  Na125I,	   0.65	  mg	  of	  protein	  
(1.3	  mg/ml),	  and	  two	  beads.	  Protein	  was	  separated	  from	  unincorporated	  125I	  with	  
a	   Sephadex	   G-­‐25	   column	   (NAPTM-­‐5	   column,	   Amersham	  Biosciences,	   8	   fractions	  
(200	  μl)	  were	  collected)	   followed	  by	  extensive	  dialysis	   (against	  0.15	  M	  NaCl,	  0.3	  
mM	   EDTA,	   pH	   7.4).	   The	   specific	   activity	   expressed	   as	   cpm/ng	   protein	   was	  
calculated	  based	  on	  the	  protein	  concentration	  measured	  by	  the	  DC	  protein	  assay	  
(Bio	   Rad)	   and	   the	   activity	   measured	   using	   a	   γ-­‐counter	   (Perkin	   Elmer).	   Specific	  
activities	  of	  600–1200	  cpm/ng	  protein	  were	  obtained.	  HDL	  or	  LDL	  was	  iodinated	  
with	   Na125I	   (Hartmann	   Analytic)	   by	   the	   McFarlane	   monochloride	   procedure	   as	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modified	   for	   lipoproteins159.	   Specific	   activities	   of	   approximately	   300	   to	   700	  
cpm/ng	  protein	  were	  obtained.	  	  
6.12. In	  vivo	  kinetics	  of	  radiolabeled	  proteins	  
Radiolabeled	  tracer	  (4	  ×	  105	   to	  8	  ×	  105	  cpm)	  was	  injected	  intravenously	  into	  the	  
recipient	  mice,	  and	  blood	  samples	  were	  obtained	  by	  saphenous	  vein	  puncture	  at	  
30	  minutes,	   1,	   2,	   3,	   5,	   8,	   and	   24	   hours.	   Twenty-­‐four	   hours	   after	   dose	   injection,	  
animals	  were	  sacrificed,	  the	  vascular	  system	  was	  flushed	  with	  15	  ml	  PBS,	  and	  the	  
liver	  kidneys	  and	  aorta	  were	  harvested	  for	  125I	  radiolabel	  quantification.	  	  
The	  transport	  of	  apoA-­‐I,	  albumin	  and	  HDL	  into	  the	  peritoneum	  was	  investigated	  as	  
follows:	   Radiolabeled	   125I-­‐HDL,	   125I-­‐apoA-­‐I	   or	   125I-­‐albumin	   was	   injected	  
intravenously.	   Six	   hours	   later,	   the	   mice	   were	   euthanized	   by	   CO2	   overdose,	  
followed	  by	  cervical	  dislocation.	  10	  ml	  of	  phosphate	  buffered	  saline	  solution	  were	  
injected	   intraperitoneally.	  This	   solution	  was	   then	  sucked	  away	  and	  processed	   to	  
measure	   the	   amount	   of	   radioactive	   125I	   HDL,	   125I-­‐apoA-­‐I,	   and	   125I-­‐albumin	  
respectively,	   that	  has	   crossed	   the	  peritoneum.	  To	  assess	   the	   transport	  of	   apoA-­‐I	  
and	   HDL	   out	   of	   the	   peritoneum,	   the	   radiolabels	   were	   injected	   intraperitoneally	  
into	   the	   mice.	   50	   μl	   of	   blood	   were	   collected	   at	   different	   time	   points	   by	   vena	  
saphena	  puncture.	  The	  mice	  were	  then	  euthanized	  after	  24	  hours	   for	   final	  blood	  
sampling	  by	  cardiac	  puncture	  and	  organ	  harvesting	   to	   count	   the	   radioactivity	   in	  
liver,	  kidney	  and	  aorta.	  
To	   assess	   the	   transport	   of	   apoA-­‐I	   through	   the	   lymph	   vessels	   of	   the	   legs,	   we	  
injected	  radiolabeled	  125I	  apoA-­‐I	   into	   the	   footpad	  and	  collected	  blood	  samples	  at	  
different	   time	  points	  as	  described.	  After	  either	   three	  or	  six	  hours,	   the	  mice	  were	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6.13. Intravital	  microscopy	  
The	   intravital	   microscopy	   was	   performed	   as	   previously	   described160.	   Male	  
C57BL/6J	  mice	  with	  a	  body	  weight	  of	  23	   to	  27	  g	   (n=7)	  were	  anesthetized	  by	  an	  
intraperitoneal	   injection	   of	   ketamine	   (90	  mg/kg	   body	  weight)	   and	   xylazine	   (25	  
mg/kg	   body	  weight).	   Before	   the	   preparation,	   animals	  were	   placed	   on	   a	   heating	  
pad	   coupled	   to	   a	   rectal	   probe.	   For	   chamber	   implantation,	   two	   symmetrical	  
titanium	  frames	  were	  mounted	  on	  a	  dorsal	  skinfold	  of	  the	  animals.	  One	  skin	  layer	  
was	   then	   completely	   removed	   in	   a	   circular	   area,	   15	   mm	   in	   diameter,	   and	   the	  
remaining	   layers	   (consisting	   of	   striated	   skin	   muscle,	   subcutaneous	   tissue,	   and	  
skin)	  were	   covered	  with	   a	   glass	   coverslip	   incorporated	   into	   one	   of	   the	   titanium	  
frames.	  Before	  skin	  grafting,	  the	  animals	  were	  allowed	  a	  recovery	  period	  of	  three	  
days.	  
	  
Figure	  7	  –	  Views	  of	  the	  front	  (left)	  and	  back	  (right)	  after	  the	  chamber	  was	  mounted	  onto	  the	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6.14. Lymphatic	  clearance	  of	  fluorescent	  proteins	  and	  markers	  	  
Lymphatic	   clearance	   was	   measured	   as	   previously	   described	   161.	   Briefly,	   five	  
microliters	  of	  P20D800	  (PEG	  conjugated	  near	  infrared	  dye),	  fluorescently	  apoA-­‐I,	  
HDL,	  LDL	  or	  albumin	  were	  intradermally	  injected	  into	  the	  footpad.	  The	  mice	  were	  
placed	   on	   an	   IVIS	   Spectrum	   imaging	   system	   (Caliper	   Life	   Sciences,	   Hopkington,	  
MA).	  Images	  were	  acquired	  at	  the	  site	  of	  injection	  after	  1,	  2,	  3,	  4,	  6	  and	  24	  hours.	  
The	  declining	  intensity	  of	  the	  tracer	  was	  then	  used	  to	  calculate	  the	  half-­‐life	  and	  K	  
rate	  using	  this	  equation:	  
I(t)	  =	  I0e-­‐kt	  
Where	  I(t)	  represents	  the	  intensity	  at	  the	  time	  t,	  I0	  is	  the	  initial	  intensity	  and	  k	  is	  
the	  exponential	  decay	  constant.	  
6.15. Macrophage-­‐to-­‐feces	  reverse	  cholesterol	  transport	  (RCT)	  
The	  RCT	  was	  performed	  as	  described	  162,163.	  J774	  cells	  were	  grown	  in	  suspension	  
in	   RPMI/HEPES	   supplemented	   with	   10%	   FBS	   and	   1%	   penicillin	   streptomycin.	  
Cells	  were	  cultured	  in	  petri	  dishes	  and	  radiolabeled	  with	  5	  μCi/mL	  3H-­‐cholesterol	  
and	  cholesterol	  loaded	  with	  25	  μg/mL	  acetylated	  LDL	  (acLDL).	  Forty-­‐eight	  hours	  
later,	   cells	   were	   washed	   with	   RPMI/HEPES	   and	   equilibrated	   for	   four	   hours	   in	  
fresh	  RPMI/	  HEPES.	  	  
On	  the	  day	  of	  injection,	  animals	  were	  caged	  individually	  with	  unlimited	  access	  to	  
food	   and	   water.	   3H-­‐cholesterol–labeled	   and	   acLDL-­‐loaded	   J774	   cells	   (typically	  
4.5x106	  cells	  containing	  7.5x106	  cpm)	  were	  injected	  intraperitoneally	  (500	  μl)	  or	  
into	  the	  footpad	  (20	  μl).	  Blood	  was	  collected	  at	  6,	  24,	  and	  48	  hours,	  and	  plasmas	  
were	  used	  for	  liquid	  scintillation	  counting	  (LSC).	  Feces	  were	  collected	  at	  48	  hours	  
and	   stored	   at	   4°C	   before	   extraction	   of	   cholesterol	   and	   bile	   acid.	   At	   study	  
termination	   (48	   hours	   after	   injection),	   mice	   were	   exsanguinated	   and	   perfused	  
with	  cold	  PBS,	  and	  portions	  of	   the	   liver	  were	  removed	  and	   flash-­‐frozen	   for	   lipid	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6.16. Endothelium	  dependent	  vasorelaxation	  	  
Endothelial	   function	   experiments	   were	   conducted,	   as	   previously	   described	   164.	  
Briefly,	   aortae	   were	   cleaned	   from	   adhering	   connective	   tissue	   and	   immediately	  
used	   for	   organ	   chamber	   experiments.	   They	   were	   cut	   into	   2-­‐3	  mm	   rings,	   which	  
were	  connected	  to	  an	  isometric	  force	  transducer	  (Multi-­‐Myograph	  610	  M,	  Danish	  
MyoTechnology,	   Denmark),	   suspended	   in	   an	   organ	   chamber	   filled	   with	   5	   mL	  
KREBS-­‐Ringer	  bicarbonate	  solution	  (37°C,	  pH7.4)	  and	  bubbled	  with	  95%	  oxygen	  
and	   5%	   CO2.	   Isometric	   tension	   was	   recorded	   continuously.	   After	   a	   30	   minutes	  
equilibration	   period,	   the	   rings	  were	   gradually	   stretched	   to	   the	   optimal	   point	   of	  
their	  length-­‐tension	  curve,	  as	  determined	  by	  the	  contraction	  to	  potassium	  chloride	  
(100	   mmol/l).	   Concentration-­‐response	   curves	   were	   obtained	   in	   a	   cumulative	  
fashion.	  Several	  rings	  were	  studied	  in	  parallel.	  Responses	  to	  acetylcholine	  (Ach	  10-­‐
9	  to	  10-­‐6	  mol/l)	  were	  recorded	  during	  submaximal	  contraction	  to	  Norepinephrine	  
(NE	  10-­‐6	  mol/l).	  Relaxations	  were	  expressed	  as	  percentages	  of	  precontraction	   to	  
norepinephrine.	  	  
	  
Figure	  8	  –	   Illustration	  of	   the	  Multi-­‐Myograph	  620	  M.	  The	  organ	  chamber	  is	  shown	  where	  the	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6.17. Monocyte	  adhesion	  to	  the	  endothelium	  
Mouse	   aortae	   were	   harvested	   after	   sacrifice	   by	   cervical	   dislocation	   and	  
immediately	   placed	   into	   DMEM	   +	   1%	   heat-­‐inactivated	   FBS.	   The	   aortae	   were	  
opened	  up	  longitudinally,	  and	  pinned	  onto	  sterile	  agar.	  The	  aortae	  were	  incubated	  
for	   30	   minutes	   with	   fluorescently-­‐labelled	   THP1	   monocytes.	   	   After	   incubation,	  
unbound	   monocytes	   were	   rinsed	   away,	   and	   the	   number	   of	   monocytes	   firmly	  
bound	   to	   aorta	   was	   counted	   in	   three	   consistent	   fields	   using	   fluorescent	  
microscopy	  165.	  As	  a	  positive	  control	  for	  adhesion,	  the	  aortae	  were	  incubated	  with	  
10	   U/mL	   tumor	   necrosis	   factor	   (TNF)-­‐alpha	   (Preprotech,	   USA)	   for	   two	   hours	  
before	  performing	  the	  assay.	  
6.18. Analysis	  of	  atherosclerotic	  lesions	  
The	  lesions	  were	  estimated	  according	  to	  Paigen	  and	  collaborators	  166.	  Briefly,	  each	  
heart	   was	   frozen	   on	   a	   cryostat	   mount	   with	   OCT	   compound	   (Tissue-­‐Tek),	   and	  
stored	  at	  −80°C.	  Hearts	  were	  cut	  using	  a	  Leica	  CM3050S	  cryostat.	  Fifty	  sections	  of	  
10-­‐μm	  thickness	  were	  prepared	  from	  the	  top	  of	  the	  left	  ventricle,	  where	  the	  aortic	  
valves	  were	  first	  visible,	  up	  to	  a	  position	  in	  the	  aorta	  where	  the	  valve	  cusps	  were	  
nearly	   disappearing	   from	   the	   field.	   After	   drying	   for	   one	   hour,	   the	   sections	  were	  
stained	   with	   oil	   red	   O	   and	   CD68	   (abcam)	   and	   counterstained	   with	   Mayer's	  
hematoxylin.	  Five	  sections	  out	  of	  the	  50,	  each	  separated	  by	  100	  μm,	  were	  used	  for	  
specific	  morphometric	  evaluation	  of	  intimal	  lesions	  using	  ImageJ.	  	  
Aortas	   were	   isolated	   and	   fixed	   in	   10%	   buffered	   formalin.	   After	   fixation,	   aortae	  
were	  cleaned	  of	  adventitial	  fat	  and	  pinned	  open	  for	  measurement	  of	  surface	  lesion	  
areas	  after	  oil	  red	  O	  staining.	  Images	  of	  en	  face	  aortas	  were	  analyzed	  using	  ImageJ	  
software	   by	   calculating	   the	   ratio	   of	   atherosclerotic	   lesions	   to	   the	   surface	   of	   the	  
entire	  aorta.	  
6.19. Statistical	  analysis	  
Data	  are	  expressed	  as	  the	  mean	  ±	  SEM.	  Statistical	  differences	  were	  assessed	  using	  
a	   2-­‐tailed	   Student’s	   t-­‐test	   (when	   comparing	   2	   datasets)	   or	   ANOVA	   (3	   or	   more	  
datasets)	  with	  Prism	  software,	  version	  4.2	  (GraphPad).	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7. Results	  
7.1. Specificity	  of	  ABCA1	  knockout	  in	  endothelial	  	  
We	   received	   three	   heterozygous	   female	   and	   male	   mice	   from	   Professor	   Parks’	  
group.	   The	   mice	   were	   bred	   and	   the	   offspring	   were	   genotyped	   to	   select	   the	  
homozygotes.	  We	  then	  expanded	  the	  colony	  to	  obtain	  a	  sufficient	  number	  of	  mice	  
to	   perform	   experiments.	   The	  mice	   did	   not	   have	   any	   developmental	   problem	   or	  
fecundity	  issues.	  No	  particular	  evidence	  of	  a	  perturbed	  behavior	  was	  observed.	  	  
One	  of	  the	  first	  experiments	  we	  performed	  consisted	  in	  confirming	  the	  specificity	  
of	  the	  knockout	  by	  verifying	  that	  the	  EC	  do	  not	  express	  ABCA1	  and	  that	  the	  other	  
cell	  types	  still	  have	  a	  level	  of	  expression	  of	  ABCA1	  comparable	  to	  control	  mice.	  We	  
first	  characterized	  the	  efficiency	  of	  the	  knockout	  of	  ABCA1	  in	  endothelial	  cells	  by	  
immunohistochemistry.	   Figure	   9	   shows	   ABCA1	   expression	   in	   mouse	   aorta	  
detected	  by	  immunofluorescence.	  Ten-­‐micron	  sections	  of	  fixed	  mouse	  aorta	  were	  
stained	   with	   a	   polyclonal	   antibody	   against	   ABCA1	   or	   a	   monoclonal	   antibody	  
against	   the	   endothelial	   cell	  marker	   CD31	   and	   counterstained	  with	   DAPI	   for	   cell	  
nuclei.	  ABCA1	  protein	  was	  highly	  expressed	   in	   the	  aortic	  endothelium	  of	  control	  
mice	  (=	  VE-­‐cadherin	  CRE	  mice)	  but	  not	  in	  Abca1e-­‐/-­‐	  mice.	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Figure	  9	  -­‐	  Characterization	  of	  aortas	  from	  an	  endothelium-­‐specific	  ABCA1	  knockout	  mouse	  
model.	   Immunofluorescence	  microscopy	  of	  the	  endothelial	  marker	  CD31	  and	  ABCA1	  in	  aortae	  of	  
control	  mice	  (upper	  row)	  and	  endothelial	  ABCA1	  knockout	  mice	  (Abca1e-­‐/-­‐,	  lower	  row).	  Note	  the	  
colocalization	  of	  ABCA1	  and	  CD31	  in	  the	  endothelium	  of	  aortae	  of	  WT	  mice	  but	  not	  of	  Abca1	  e-­‐/-­‐	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Figure	  10	  -­‐	  Immunostaining	  of	  microvessels	  in	  lung	  tissues.	  CD31	  (red),	  ABCA1	  (green)	  and	  
DAPI	  (blue)	  signals	  are	  shown	  in	  control	  (upper	  panel)	  as	  well	  as	  KO	  tissue	  (lower	  panel).	  
Note	  the	  lack	  of	  colocalization	  of	  ABCA1	  and	  CD31	  in	  the	  microvasculature	  of	  the	  knockout	  tissue.	  
Scale	  bars:	  40	  µm.	  
We	   also	   tested	   whether	   the	   microvasculature	   is	   affected	   by	   the	   knockout	   and,	  
therefore,	   stained	   the	   lung	  of	   control	   and	  KO	  mice.	  Figure	   10	   illustrates	  ABCA1	  
expressed	   in	   the	  microvasculature	   of	   the	   lung,	   ABCA1	   colocalized	  with	   CD31	   in	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We	   performed	   a	   similar	   staining	   in	   the	   lymphatic	   vessels	   of	   the	   tail	   skin	   from	  
control	  and	  Abca1e-­‐/-­‐	  mice	  (Figure	  11).	  Here	  again	  the	  staining	  demonstrates	  no	  
colocalization	   of	   ABCA1	  with	   CD31	   in	   KO	   tissue.	  We	   observe	   a	   colocalization	   of	  
LYVE1	   (lymphatic	   endothelial	   cells	   marker)	   with	   ABCA1	   in	   control,	   but	   not	   KO	  
tissue.	   These	   data	   show	   that	   the	   knockout	   of	   ABCA1	   affects	   the	   macro-­‐	   and	  
microvasculature	  including	  the	  lymphatic	  system.	  	  
	  
Figure	   11	   -­‐	   Immunostaining	   of	   the	   tail	   skin	   of	   KO	   and	   control	   mice	   showing	   LYVE1	  
(lymphatic	  endothelial	  marker),	  CD31	  and	  ABCA1.	  An	  example	  of	  ABCA1	  being	  colocalised	  with	  
both	  CD31	  and	  LYVE1	   in	   lymphatic	  vessels	   is	  shown	  by	  pink	  arrows.	  Another	  example	  of	  ABCA1	  
being	  colocalised	  with	  CD31	  but	  not	  LYVE1	  in	  capillaries	   is	   indicated	  by	  white	   lymphatic	  vessels.	  
Note,	   that	  here	   is	  no	  colocalization	  of	  ABCA1	  with	  CD31	  or	  LYVE1	   in	   the	  skin	  of	  Abca1e-­‐/-­‐	  mice.	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As	  the	  VE-­‐cadherin	  CRE	  mice	  have	  been	  reported	  to	  express	   low	  amounts	  of	  VE-­‐
cadherin	   in	   hematopoietic	   cells	   150,	   we	   isolated	   and	   differentiated	  macrophages	  
from	  bone	  marrow	  of	  Abca1e-­‐/-­‐	  and	  control	  mice	  to	  test	  their	  ABCA1	  expression.	  
By	  using	  RT-­‐PCR	  and	  western	  blotting	  we	  observed	  normal	  ABCA1	  expression	  in	  
bone	  marrow-­‐derived	  macrophages.	  Treatment	  with	  an	  LXR	  agonist	  (T0901317)	  
markedly	   increased	   ABCA1	   expression	   in	   both	   groups	   (Figure	   12).	   We	   also	  
observed	   similar	   expression	  of	  ABCA1	   in	   the	   liver,	   spleen,	   brain	   and	   the	   lung	  of	  
Abca1e-­‐/-­‐	  mice.	  Notably,	  ABCA1	  protein	  expression	  was	  markedly	  reduced	  in	  the	  
kidneys	  of	  Abca1e-­‐/-­‐	  mice,	  probably	  reflecting	  the	  high	  degree	  of	  vascularization	  
in	  this	  organ	  (Figure	  13).	  
	  
Figure	  12	   –	  Expression	  of	  ABCA1	   in	  bone	  marrow	  derived	  macrophages	   from	  control	   and	  
Abca1e-­‐/-­‐	   mice.	   (A)	   RT-­‐PCR	   showed	   same	   levels	   of	   ABCA1	   expression	   in	   both	   genotypes.	   (B)	  
Western	  blot	   analysis	   of	   cell	   lysates	   shows	  ABCA1	  and	  actin	   expression	   after	  18	  h	  of	   incubation	  
with	  or	  without	  10	  µM	  T0901317	  (LXR	  agonist).	  	  
	  
Figure	  13	  –	  Expression	  of	  ABCA1	  in	  various	  organs	  of	  control	  and	  Abca1e-­‐/-­‐	  mice.	  Note	  the	  
normal	  expression	  of	  ABCA1	  in	  all	  tissues	  in	  mice	  with	  endothelial	  knockout	  of	  ABCA1	  (KO)	  mice	  
as	   compared	   to	   control	   mice	   (CTL).	   The	   lower	   concentration	   in	   lung	   and	   kidney	   reflects	   the	  
absence	  of	  endothelial	  ABCA1	  in	  these	  highly	  vascularized	  organs.	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7.2. Plasma	  lipids	  and	  lipoproteins	  
Upon	   both	   chow	   diet	   and	   high-­‐fat/high	   cholesterol	   (HFHC)	   diet,	   Abca1e-­‐/-­‐	   and	  
control	  mice	  did	  not	  differ	  in	  body	  or	  organ	  weight	  (Figure	  14).	  We	  then	  analysed	  
the	  plasma	  samples	  of	  Abca1e-­‐/-­‐	  and	  control	  mice	  for	  concentrations	  of	  lipids	  and	  
lipoproteins.	  We	  collected,	  every	  four	  weeks,	  after	  4-­‐5	  hours	  of	   fasting,	  200	  µl	  of	  
blood	   from	   the	   saphenous	   vein	   of	   the	   different	   groups.	   Total	   cholesterol	   and	  
triglycerides	   were	   measured	   in	   the	   samples	   of	   eight	   mice	   animals	   per	   group.	  
Figure	   15A	   and	   B	   show	   the	   development	   of	   these	   parameters	   overtime	   in	   the	  
HFHC	   group.	   The	   total	   cholesterol	   level	   plasma	   level	   of	   our	   mice	   increased	  
significantly	  over	  12	  weeks	  of	  HFHC	  diet.	  No	  significant	  differences	  were	  observed	  
when	   comparing	   the	   different	   genotypes.	   Of	   note,	   the	   triglyceride	   plasma	   level	  
decreased	  in	  all	  our	  groups	  without	  significant	  differences	  between	  the	  genotypes	  
(Table	  2).	  
	  
Figure	   14	   –	   Body	   and	   organ	   weight	   of	   control	   and	   knockout	   mice.	   (A)	  Weight	   curves	   of	  
Abca1e-­‐/-­‐	  and	  control	  mice.	   (B-­‐E)	  Weight	  of	   liver,	  kidney,	  spleen	  and	  brown	  fat	  after	  sacrifice	  of	  
chow	  and	  HFHC	  diet	  fed	  group	  in	  knockout	  and	  control	  mice.	  




Figure	   15	   –	   Plasma	   cholesterol	   (A)	   and	   triglyceride	   (B)	   of	   Abca1e-­‐/-­‐	   and	   control	  mice	   on	  
HFHC	  diet.	  No	  difference	  in	  these	  parameters	  was	  observed	  between	  the	  two	  groups.	  
	  
Chow	  diet	   HFHC	  diet	  
	  
Control	   Abca1e-­‐/-­‐	   Control	   Abca1e-­‐/-­‐	  
TC	  [mmol/l]	   3.16	  ±	  0.53	   3.35	  ±	  0.26	   5.06	  ±	  2.1	   5.35	  ±	  0.39	  
TG	  [mmol/l]	   1.19	  ±	  0.27	   0.97	  ±	  0.28	   0.61	  ±	  0.05	   0.7	  ±	  0.05	  
PL	  [mg/dl]	   217.1	  ±	  13.2	   180.2	  ±	  12.1	   231.4	  ±	  10.3	   201.3	  ±	  11.4	  
Table	  2	  -­‐	  Plasma	   lipids	  of	  endothelial-­‐specific	  knockout	  mice.	  Values	  are	  mean	  ±	  SEM.	  Blood	  
was	  obtained	  for	  analyses	  from	  chow	  or	  High	  fat	  cholesterol	  diet-­‐fed	  mice	  that	  were	  9–12	  weeks	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The	   lipoprotein	   distribution	   of	   cholesterol	   and	   phospholipids	   of	   Abca1e-­‐/-­‐	  mice	  
was	  tested	  by	  Fast	  protein	  liquid	  chromatography	  (FPLC)	  to	  reveal	  any	  change	  in	  
the	  concentration	  or	  the	  particle	  size	  of	  VLDL,	  LDL	  and	  HDL.	  Abca1e-­‐/-­‐	  and	  control	  
mice	  did	  not	   differ	   significantly	   by	   concentration	   or	   particle	   size	   of	   lipoproteins	  
(Figure	  16).	  
	  
Figure	  16	  –	  Cholesterol	  and	  phospholipid	  profiles	  in	  pooled	  plasma	  of	  chow	  (A,	  C)	  and	  HFHC	  
(B,	  D)	   fed	   control	   and	  Abca1	   e-­‐/-­‐mice.	  No	  difference	   in	  cholesterol	  distribution	  was	  observed.	  
Neither	   difference	   was	   found	   in	   phospholipid	   distribution	   (C)	   and	   (D)	   in	   chow	   or	   HFHC	   diet	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7.3. Glucose	  and	  insulin	  
It	   has	   been	   shown	   that	   ABCA1	   in	   pancreatic	   beta-­‐cells	   has	   a	   critical	   function	   in	  
regulating	   glucose	   homeostasis.	   Its	   absence	   leads	   to	   defective	   insulin	   secretion	  
and	   impairment	   of	   glucose	   tolerance	   167.	   Another	   study	   has	   shown	   that	   islet	  
endothelial	  cells	  are	   involved	  not	  only	   in	  the	  delivery	  of	  oxygen	  and	  nutrients	  to	  
endocrine	  cells,	  but	   induce	   insulin	  gene	  expression	  during	   islet	  development	   168.	  
The	  Abca1e-­‐/-­‐	  mice	  did	  not	  show	  any	  difference	  in	  glucose	  plasma	  concentration	  
compared	  to	  control	  mice	  over	  HFHC	  diet	  (Figure	  17).	  Therefore,	  we	  decided	  to	  
test	  the	  effect	  of	  endothelial	  ABCA1	  in	  glucose	  tolerance	  and	  insulin	  secretion.	  	  
After	  an	  overnight	  fasting,	  we	  injected	  each	  animal	  i.p.	  with	  glucose	  (2	  g/kg	  body	  
weight).	   Samples	   for	   determination	   of	   blood	   glucose	   and	   insulin	   concentrations	  
were	  obtained	  at	  different	  time	  points	  from	  the	  tail	  tip.	  	  
	  
Figure	  17	  –	  Glucose	  plasma	  level	  of	  Abca1e-­‐/-­‐	  and	  control	  mice	  on	  HFHC	  diet.	  N=8	  mice	  per	  
group	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Figure	   18	   –	   Glucose	   (A,	   B)	   and	   insulin	   levels	   (C,	   D)	   during	   the	   intraperitoneal	   glucose	  
tolerance	  test	  of	  knockout	  and	  control	  mice	  on	  chow	  (A,	  C)	  and	  HFHC	  diet	  (B,	  D).	  We	  observe	  
a	  lower	  peak	  level	  after	  glucose	  injection	  in	  the	  knockout	  mice	  compared	  to	  control.	  This	  difference	  
was	  significant	  for	  the	  HFHC	  group	  as	  shown	  on	  the	  AUC	  (E).	  Insulin	  concentrations	  were	  always	  
higher	  in	  the	  Abca1e-­‐/-­‐	  mice.	  *	  P	  <	  0.05,	  **	  P	  <	  0.01;	  n=7-­‐8	  mice	  per	  group.	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Figure	  18,	  Abca1e-­‐/-­‐	  mice	  demonstrate	  a	  lower	  peak	  concentration	  of	  glucose	  and	  
faster	  normalization	  of	  glucose	  levels.	  This	  difference	  is	  even	  more	  pronounced	  for	  
the	   HFHC	   group.	   When	   measuring	   insulin	   during	   the	   same	   experiment,	   we	  
observe	  higher	   insulin	   levels	   in	   the	  knockout	  compared	   to	  control	  mice,	   at	  most	  
time	   points.	   Interestingly,	   the	   ITT	   experiment	   shows	   no	   difference	   in	   insulin	  
sensitivity	  (Figure	  19).	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Figure	  19	  –Effect	  of	  intraperitoneal	  insulin	  tolerance	  test	  on	  glucose	  levels.	  	  After	  injection	  of	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7.4. Metabolism	  of	  radioactive	  apoA-­‐I	  and	  HDL	  	  
It	   has	   been	   shown	   that	   HDL	   particles	   undergo	   enhanced	   catabolism	   in	   patients	  
with	  Tangier	  disease	  169.	  Timmins	  et	  al.	  110	  have	  demonstrated	  that	  radioactively	  
labeled	   HDL	   and	   lipid-­‐free	   apoA-­‐I	   are	   faster	   removed	   in	   liver	   specific	   ABCA1	  
knockout	   mice	   compared	   to	   control	   mice.	   At	   the	   end	   of	   the	   experiment,	   the	  
authors	   have	   observed	   that	   the	   liver	   and	   the	   kidney	   of	   the	   knockout	   mice	   had	  
higher	  radioactive	  counts	  than	  the	  respective	  organs	  of	  the	  control	  mice,	  proving	  
the	  higher	  catabolism.	  This	  accelerated	  removal	  of	  apoA-­‐I	  and	  HDL	  from	  the	  blood	  
of	   Tangier	   disease	   patients	   or	   liver-­‐specific	   ABCA1	   knockout	  mice	   is	   due	   to	   the	  
failing	   lipidation	   of	   apoA-­‐I	   into	  mature	  HDL	   particles.	  We,	   therefore,	   decided	   to	  
test	  whether	  the	  absence	  of	  endothelial	  ABCA1	  would	  also	  play	  a	  role	  in	  lipid-­‐free	  
apoA-­‐I	  catabolism,	  following	  the	  same	  procedure	  as	  Timmins	  et	  al.	  
After	  injection	  of	  radio-­‐iodinated	  apoA-­‐I,	  we	  found	  no	  differences	  in	  the	  decay	  of	  
plasma	   radioactivity	   (Figure	   20),	   in	   the	   radioactivity	   excreted	   with	   urine	   and	  
feces,	   and	   in	   the	   accumulation	   of	   radiolabel	   in	   liver	   and	   kidney	   (Figure	   20B),	  
However,	   compared	   to	   aortae	   of	   control	   mice,	   the	   aortae	   of	   ABCA1e-­‐/-­‐	   mice	  
showed	  significantly	  reduced	  accumulation	  of	  the	  radiolabel	  (Figure	  20C).	  Similar	  




Results	   	  
57	  
	  
Figure	   20	   -­‐	   Metabolism	   of	   radiolabeled	   apoA-­‐I	   and	   HDL	   in	   control	   and	   mice	   with	  
endothelium-­‐specific	   knockout	   of	   ABCA1.	  No	   genotype-­‐dependent	  differences	  were	   found	   for	  
the	  decay	  of	  radiolabel	  from	  plasma	  (A	  and	  D),	  for	  the	  24h-­‐excretion	  of	  radiolabel	  with	  feces	  and	  
urine,	   and	   for	   the	   24h-­‐uptake	   of	   radiolabel	   into	   liver	   and	   kidney	   (B	   and	   E).	   However,	   after	   24	  
hours,	  Abca1e-­‐/-­‐	  mice	  accumulated	  less	  apoA-­‐I	  and	  HDL	  within	  the	  aorta	  (C	  and	  F).*	  P	  <	  0.05;	  n=4-­‐
6	  mice	  per	  group.	  
By	  contrast,	   LDL	  or	   albumin	   (Figure	   21A	   and	  B)	  did	  not	   accumulate	  differently	  
within	  the	  aortae	  of	  control	  and	  ABCA1e-­‐/-­‐	  mice.	  
	  
Figure	  21	  –	  Albumin	  (A)	  and	  LDL	  (B)	  show	  no	  difference	  in	  accumulation	  in	  the	  aorta.	  Data	  
represent	  the	  mean	  ±	  SEM	  comparing	  indicated	  conditions.	  n=4-­‐5	  mice	  per	  group.	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To	   further	   support	   the	   limiting	   impact	   of	   ABCA1	   towards	   the	   accumulation	   of	  
apoA-­‐I	   within	   the	   aortic	   wall,	   we	   investigated	   the	   uptake	   of	   a	   mutant	   form	   of	  
apoA-­‐I,	   namely	   apoA-­‐I[L218/L219/V221/L222]	  which	  was	   generously	   provided	  
by	  Professor	  Zannis,	  and	  which	  does	  not	  interact	  with	  ABCA1,	  as	  demonstrated	  by	  
its	  inability	  to	  elicit	  any	  ABCA1-­‐dependent	  lipid	  efflux	  or	  to	  form	  HDL	  particles	  170.	  
As	  previously	  shown	  by	  our	  group	  91,	  this	  apoA-­‐I	  isoform	  with	  a	  mutated	  carboxyl	  
terminus	   is	   not	   transcytosed	   through	   endothelial	   cells	   in	   vitro.	   We	   observed	   a	  
faster	   removal	   from	   plasma	   (Figure	   22A)	   and	   accelerated	   renal	   and	   hepatic	  
uptake	   (Figure	   22B)	  of	   the	   radioidinated	  apoA-­‐I	  mutant	   compared	   to	  wild-­‐type	  
apoA-­‐I	  in	  both	  control	  and	  Abca1e-­‐/-­‐	  mice.	  	  
	  
Figure	   22	   -­‐	  Metabolism	   of	  mutant	   versus	  wild	   type	   apoA-­‐I	   in	   Abca1e-­‐/-­‐	  mice	   and	   control	  
mice.	   (A)	   The	   mutant	   apoA-­‐I	   with	   four	   carboxyterminal	   amino	   acid	   substitutions	   disappeared	  
faster	   from	   the	   plasma	   compartment	   as	   compared	   to	  wild	   type	   apoA-­‐I	   in	   control	   and	  Abca1e-­‐/-­‐	  
mice,	  which	  was	  due	  to	  a	  higher	  catabolism	  in	  the	  kidney	  and	  liver	  (B).	  *	  P	  <	  0.05,	  **	  P	  <	  0.01;	  n=7-­‐
8	  mice	  per	  group.	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This	  hypercatabolism	   is	   explained	  by	   the	   lack	  of	   in	  vivo	   lipidation	  of	   the	  mutant	  
apoA-­‐I,	  which	  leads	  to	  faster	  renal	  excretion.	  We	  also	  observed	  a	  reduced	  uptake	  
of	   the	  mutant	  apoA-­‐I	   relative	   to	  wild	   type	  apoA-­‐I	   into	   the	  aortae	  of	  both	  control	  
and	  Abca1e-­‐/-­‐	  mice.	  Of	  note	  and	  in	  line	  with	  our	  hypothesis,	  the	  accumulation	  of	  
mutant	   apoA-­‐I	   did	   not	   differ	   between	   aortae	   of	   Abca1e-­‐/-­‐	   and	   control	   mice	  
(Figure	   23).	   These	   observations	   further	   support	   our	   hypothesis	   that	  
compromised	  apoA-­‐I/ABCA1	  interaction	  in	  the	  endothelium	  limits	  the	  abundance	  
of	  apoA-­‐I	  within	  the	  arterial	  wall	  of	  the	  aorta.	  	  
	  
Figure	  23	  -­‐	  The	  mutant	  apoA-­‐I	  accumulated	  to	  a	  lesser	  degree	  in	  the	  aorta	  of	  control	  mice	  as	  
well	   as	   Abca1e-­‐/-­‐	   mice	   compared	   to	   wild	   type	   apoA-­‐I	   in	   wild	   type	  mice.	   Interestingly,	   the	  
endothelial	   specific	   apoA-­‐I	   knockout	   led	   to	   the	   reduced	   accumulation	   in	   the	   aorta	   of	   wild	   type	  
apoA-­‐I	   but	   not	   the	   mutated	   apoA-­‐I.	   Data	   represent	   the	   mean	   ±	   SEM	   comparing	   indicated	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7.5. 	  Investigation	  of	  microvascular	  transport	  by	  intravital	  microscopy	  
In	  order	  to	  confirm	  our	  observation	  of	  a	  decreased	  accumulation	  of	  apoA-­‐I	  within	  
the	   aorta,	   we	   decided	   to	   take	   an	   in	   vivo	   imaging	   approach.	   The	   question	   we	  
wanted	   to	   answer	   was	   how	   the	   vasculatures	   of	   the	   Abca1e-­‐/-­‐	   mouse	   in	  
comparison	   with	   wild	   type	   mice	   are	   taking	   up	   fluorescently	   labelled	   apoA-­‐I	   or	  
HDL.	   We	   collaborated	   with	   Dr.	   Lindenblatt	   at	   the	   Division	   of	   Plastic	   and	   Hand	  
Surgery	   at	   the	   University	   Hospital	   of	   Zurich,	   who	   established	   this	   method	  
previously	  160.	  
We	  implanted	  a	  dorsal	  skinfold	  chamber	  on	  the	  back	  of	  the	  shaved	  mice.	  Two	  days	  
later	  after	  recovery,	  fluorescently	  labelled	  apoA-­‐I	  was	  injected	  i.v.	  and	  the	  uptake	  
of	   the	   fluorescent	   apoA-­‐I	   or	  HDL	   by	   the	  microvasculature	  was	   recorded	   by	   two	  
photon	  microscope	  with	  the	  help	  of	  the	  chamber.	  We	  tested	  different	  time	  points	  
to	  observe	   the	  appearance	  of	   fluorescent	  apoA-­‐I	   in	   the	  microvasculature.	  Figure	  
24	   displays	   a	   close	   look	   of	   the	   microvasculature	   one	   hour	   after	   injection.	   We	  
observe	  a	  bright	  signal	  coming	  from	  apoA-­‐I	  along	  macro	  and	  microvessels.	  
	  
Figure	  24	  -­‐	  Intravital	  microscopy	  picture	  showing	  in	  green	  the	  fluorescently	  labeled	  apoA-­‐I	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Figure	   25	   shows	  a	  magnification	  of	   one	  microvessel	   that	  has	  been	  observed	  up	  
until	  three	  hours	  after	  injection	  of	  the	  label.	  Unfortunately	  and	  probably	  due	  to	  the	  
limited	  resolution	  of	  the	  two	  photon	  microscope,	  we	  did	  not	  observe	  any	  uptake	  of	  
apoA-­‐I	  within	  the	  aorta	  three	  hours	  after	  injection.	  
	  
Figure	  25	  –	  Magnification	  of	  a	  microvessel.	  After	  a	  closer	  look	  we	  do	  not	  observe	  any	  uptake	  of	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7.6. Effect	  of	  endothelial	  ABCA1	  on	  lymphatic	  apoA-­‐I	  transport	  	  
The	  different	  accumulation	  of	  apoA-­‐I	  in	  the	  aortae	  of	  control	  and	  Abca1e-­‐/-­‐	  mice	  
could	  be	  the	  result	  of	  either	  decreased	  influx	  through	  the	  luminal	  endothelium	  or	  
increased	  efflux	  through	  the	  vasa	  vasorum	  or	  lymphatic	  vessels.	  Previous	  research	  
in	  mice	  indicated	  that	  HDL	  is	  cleared	  from	  interstitial	  compartments,	  including	  the	  
aorta	   and	   the	   subcutaneous	   tissue	   of	   the	   footpad,	   via	   lymphatic	   vessels	   163,171.	  
Therefore,	  we	   investigated	  the	   impact	  of	   the	  endothelial	  ABCA1	  knockout	  on	  the	  
structure	  and	  function	  of	  the	  lymphatic	  vessels.	  
Immunofluorescence	   microscopy	   and	   further	   quantification	   of	   the	   lymphatic	  
vessel	   marker	   LYVE-­‐1	   revealed	   no	   difference	   in	   the	   number	   and	   structure	   of	  
lymphatic	  vessels	  in	  the	  ears	  of	  control	  and	  Abca1e-­‐/-­‐	  mice	  (Figure	  26).	  	  
	  
Figure	   26	   –	   Structure	   of	   the	   lymphatics	   in	   control	   and	   Abca1e-­‐/-­‐	   depicted	   by	  
immunofluorescence	   microscopy.	   (A)	   Overview	   pictures	   of	   ear	   LYVE-­‐1	   whole	   mount	  
immunostains.	   Scale	   bars:	   2	   mm	   and	   500	   µm.	   (B)	   Quantification	   of	   ear	   lymphatic	   vascular	  
parameters.	   Data	   represent	   the	   mean	   ±	   SD	   comparing	   indicated	   conditions.	   (C)	   Compilation	   of	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close	  up	  confocal	  images	  representing	  blood	  vessels	  (in	  red)	  and	  lymphatic	  vessels	  (in	  green)	  that	  
show	  a	  similar	  morphology	  in	  KO	  and	  control	  mice.	  Scale	  bar:	  200	  µm.	  
	  
Figure	  27	  –	  Measurement	  of	  the	  lymphatic	  clearance	  of	  a	  P20D800	  tracer	  in	  a	  control	  mouse	  
(A)	  Acquisition	  of	   the	  mouse	   footpad	  using	   the	   IVIS	   spectrum,	   immediately	  after	   injection	  of	   the	  
P20D800	   tracer.	   (B)	   The	   fluorescent	   signal	   intensity	   was	   measured	   at	   different	   timepoint	   and	  
plotted	  on	  a	  graph.	  	  
To	   study	   the	   functionality	   of	   lymphatic	   drainage,	   we	   injected	   near-­‐infrared	  
fluorescently	   labeled	   Methoxypoly	   20	   kDa	   methoxypoly(ethylene	   glycol)	   (PEG)	  
amine	  (P20D800),	  a	  tracer	  known	  to	  be	  specifically	  cleared	  via	  lymphatic	  vessels	  
172,	  into	  the	  dermis	  of	  footpads	  of	  control	  and	  knockout	  mice	  and	  acquired	  images	  
over	  time	  using	  an	  IVIS	  Spectrum	  (Figure	  27).	  As	  shown	  in	  Figure	  28A,	  B	  and	  C,	  
the	  lymphatic	  clearance	  of	  P20D800	  did	  not	  differ	  between	  Abca1e-­‐/-­‐	  and	  control	  
mice.	   Additionally,	   the	   clearance	   rates	   of	   both	   the	   apoA-­‐I	   (Figure	   29A	   to	  C)	   or	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HDL	  (Figure	  29D	   to	  F)	  did	  not	  differ	  between	  the	  knockout	  mice	  and	  the	  control	  
mice.	  	  
	  
Figure	   28	   –	   Measure	   of	   the	   lymphatic	   clearance	   of	   the	   P20D800	   tracer	   in	   control	   and	  
knockout	  mice.	  The	  disappearance	  of	  the	  tracer	  at	  the	  site	  of	  injection	  was	  measured	  (A)	  and	  the	  
half-­‐life	  (B)	  and	  Krate	  (C)	  were	  calculated	  accordingly.	  
	  
Figure	  29	  –	  Measure	  of	  the	  lymphatic	  clearance	  of	  fluorescently	  labeled	  apoA-­‐I	  (A,	  B	  and	  C)	  
and	  HDL	  (D,	  E	  and	  F).	  In	  both	  cases	  no	  significant	  difference	  in	  lymphatic	  clearance	  was	  observed.	  
Data	  represent	  the	  mean	  ±	  SEM	  comparing	  indicated	  conditions.	  *P	  <	  0.05;	  n=5-­‐6	  mice	  per	  group.	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To	   further	   support	   this	   finding,	  we	   repeated	   the	   experiment	   by	   the	   injection	   of	  
radiolabeled	  apoA-­‐I	  into	  the	  footpads.	  After	  either	  three	  or	  six	  hours,	  we	  sacrificed	  
the	  mice	   to	   obtain	   blood	   and	   popliteal	   lymph	   nodes.	   The	   radioactivity	   was	   not	  
significantly	   different	   between	   control	   and	   Abca1e-­‐/-­‐	   mice	   in	   both	   plasma	   and	  
lymph	  nodes	  (Figure	  30).	  
	  
Figure	  30	  –	  Clearance	  of	  radioactively	  labelled	  apoA-­‐I	  after	  footpad	  injection.	  (A)	  Appearance	  
of	  radioactively	  labeled	  apoA-­‐I	  in	  the	  plasma	  after	  footpad	  injection	  over	  time.	  (B)	  Collection	  of	  the	  
popliteal	  lymph	  node	  3	  and	  6	  hours	  after	  footpad	  injection.	  No	  difference	  in	  plasma	  accumulation	  
or	   lymph	  node	  retention	  was	  observed	  between	  the	  two	  strains.	  Data	  represent	  the	  mean	  ±	  SEM	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The	   peritoneum	   is	   another	   tissue	   that	   is	   highly	   vascularized	   by	   microvessels,	  
including	   lymphatics.	   To	   assess	   the	   transport	   of	   apoA-­‐I	   and	   HDL	   out	   of	   the	  
peritoneum,	  we	  injected	  radiolabeled	  HDL	  and	  apoA-­‐I	  i.p.	  and	  measured	  the	  time	  
kinetics	   by	   which	   the	   radioactive	   label	   enters	   and	   leaves	   the	   circulation.	   The	  
Abca1e-­‐/-­‐	  and	  control	  mice	  did	  not	  differ	  by	   the	  appearance	  of	   radiolabel	   in	   the	  
blood	  (Figure	  31	  A	  and	  C).	  In	  order	  to	  assess	  the	  transport	  of	  apoA-­‐I	  and	  HDL	  into	  
the	  peritoneum,	  we	  injected	  radiolabeled	  HDL	  and	  apoA-­‐I	  intravenously.	  Six	  hours	  
later,	   the	   mice	   were	   euthanized.	   We	   then	   performed	   a	   peritoneal	   lavage	   by	  
injecting	  ten	  millilitres	  of	  phosphate	  buffered	  saline	  solution	  i.p.	  This	  solution	  was	  
then	   removed	   through	   suction	   and	   processed	   to	   measure	   the	   amount	   of	  
radioactive	  label	  that	  has	  crossed	  the	  peritoneum.	  No	  difference	  in	  the	  amount	  of	  
apoA-­‐I	  and	  HDL	   that	  has	  crossed	   the	  peritoneum	  coming	   from	  the	  blood	  stream	  
was	  observed	  (Figure	  31	  B	  and	  D).	  
	  
Figure	  31	  –	  Strategies	  to	  measure	  the	  transport	  of	  apoA-­‐I	  and	  HDL	  through	  the	  peritoneum.	  
The	  transport	  of	  apoA-­‐I	  and	  HDL	  through	  the	  peritoneum	  was	  tested	  by	  IP	  injection	  of	  radioactive	  
label	  and	  plasma	  counting,	  as	  well	  as	  i.v.	  injection	  and	  peritoneal	  lavage.	  The	  recovery	  of	  apoA-­‐I	  (A	  
and	  B)	  or	  HDL	  (C	  and	  D)	  was	  not	  perturbed	  in	  the	  two	  mouse	  strains;	  n=5-­‐6	  mice	  per	  group.	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7.7. Macrophage	   specific	   reverse	   cholesterol	   transport	   is	   not	   affected	   by	   the	  
knockout	  of	  ABCA1	  in	  the	  endothelium	  
One	   proposed	   atheroprotective	   mechanism	   of	   HDL	   is	   the	   transport	   of	   excess	  
cholesterol	   by	  macrophages	   to	   the	   liver	   for	   excretion.	   However,	   HDL	  must	   pass	  
endothelial	  layers	  at	  least	  twice	  in	  order	  for	  this	  process	  to	  take	  place,	  namely	  for	  
the	  entry	  into	  arterial	  wall	  via	  the	  luminal	  endothelium	  and	  for	  departure	  through	  
the	   endothelium	   of	   lymphatics.	   Therefore,	   we	   investigated	   the	   impact	   of	  
endothelial	   ABCA1	   deficiency	   in	   two	   mouse	   models	   of	   macrophage-­‐specific	  
reverse	   cholesterol	   transport.	   First,	   we	   injected	   J774	   macrophages	   loaded	   with	  
radioactive	  cholesterol	   into	   the	  peritoneal	  cave	  of	  control	  and	  Abca1e-­‐/-­‐	  mice	   to	  
record	   the	  appearance	  of	   radiolabel	   in	  plasma,	   liver	  and	   feces.	  At	  all-­‐time	  points	  
up	   to	  48	  hours,	  we	  did	  not	  observe	  any	  differences	   in	  appearance	  of	   radioactive	  
cholesterol	   in	   the	   plasma	   of	   the	   knockout	   mice	   compared	   to	   the	   control	   mice	  
(Figure	   32A).	   Likewise,	   the	  percent	   radioactivity	   recovered	   in	   the	   liver	   and	   the	  
feces	  after	  48	  hours	  was	  slightly,	  but	  insignificantly	  lower	  in	  Abca1e-­‐/-­‐	  mice	  than	  
in	  control	  mice	  (Figure	  32B).	  	  
In	  the	  second	  RCT	  model,	  which	  was	  first	  described	  by	  Lim	  163	   to	   investigate	  the	  
role	  of	  lymphatic	  vessels	  for	  	  reverse	  cholesterol	  transport,	  3H-­‐cholesterol	  labeled	  
macrophages	  were	  injected	  into	  the	  footpad.	  Blood,	  feces,	  liver	  and	  footpad	  were	  
harvested	  48	  hours	  after	  the	  experiment	  for	  the	  measurement	  of	  radioactivity,	  as	  
described	  above.	  As	  depicted	  in	  Figure	  32C	  and	  D,	  Abca1e-­‐/-­‐	  and	  control	  mice	  did	  
not	   differ	   significantly	   with	   regards	   to	   the	   appearance	   of	   radiolabel	   in	   plasma,	  
liver	  or	  feces.	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Figure	  32	  -­‐	  Reverse	  transport	  of	  cholesterol	  from	  macrophages	  into	  the	  peritoneal	  cavity	  (A	  
and	  B)	  or	  the	  footpad	  (C	  and	  D)	  of	  control	  and	  Abca1e-­‐/-­‐	  mice.	  In	  both	  models,	  we	  observed	  a	  
similar	   appearance	   of	   cholesterol	   in	   the	   plasma	   of	   Abca1e-­‐/-­‐	   mice.	   Forty-­‐eight	   hours	   after	   the	  
macrophage	   administration,	   we	   also	   observed	   similar	   uptake	   in	   the	   feces	   and	   liver	   of	   the	   KO	  
compared	   to	   control	   mice.	   All	   data	   represent	   the	   mean	   ±	   SEM	   comparing	   indicated	   conditions;	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7.8. Endothelial	  vasorelaxation	  is	  attenuated	  in	  ABCA1e-­‐/-­‐	  mice	  
Terasaka	   et	   al	   69	   have	   previously	   shown	   disturbed	   endothelial	   dependent	  
vasorelaxation	   in	  mice	  with	   a	   global	   knockout	   of	   ABCA1.	   Since	   these	  mice	   have	  
very	   low	   levels	   of	  HDL,	   it	   is	   not	   clear	  whether	   this	   defect	  was	   a	   direct	   effect	   of	  
ABCA1	   lacking	   from	   endothelial	   cells	   or	   an	   indirect	   effect	   of	  HDL	   deficiency.	   To	  
address	  this	  question,	  aortae	  were	  isolated	  from	  Abca1e-­‐/-­‐	  and	  control	  mice,	  after	  
16	   weeks	   of	   chow	   diet	   or	   HFHC	   diet.	   In	   aortic	   rings	   during	   submaximal	  
contraction	   to	   norepinephrine	   (NE),	   concentration-­‐response	   curves	   in	   response	  
Acetylcholine	  were	  measured.	  Aortic	  vasorelaxation	  was	  attenuated	  in	  Abca1e-­‐/-­‐	  
mice	  fed	  on	  chow	  and	  HFHC	  diet	  (Figure	  33A	  and	   B).	  Upon	  chow	  diet	  the	  EC50	  
values	  for	  the	  response	  to	  ACh	  was	  almost	  3-­‐fold	  greater	  in	  Abca1e-­‐/-­‐	  mice	  (34.9	  +	  
1.73	   nmol/L)	   than	   in	   control	   mice	   (13.1	   +	   1.76	   nmol/L;	   P	   <	   0.01).	   After	   HFHC	  
feeding	  the	  EC50	  values	  differed	  by	  nearly	  factor	  2:	  23.1	  +	  1.74	  nmol/L	  vs.	  11.0	  +	  
1.6	  nmol/L	  (P	  <	  0.01)	  (Figure	  33C).	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Figure	   33	   –	   Effect	   of	   the	   endothelial	   ABCA1	   knock-­‐out	   on	   the	   acetylcholine	   induced	  
relaxation	   of	   aortic	   rings.	   (A)	   Control	   and	   Abca1e-­‐/-­‐	   aortic	   rings	   were	   tested	   for	   endothelial	  
dysfunction.	   Vasorelaxation	   in	   response	   to	   ACh	   was	   significantly	   attenuated	   in	   Abca1e-­‐/-­‐	   mice	  
compared	  to	  control.	   (B)	  Same	  observation	   is	  made	  when	  the	  mice	  were	   fed	  HFHC	  diet.	   (C)	  EC50	  
values	  of	  vasorelaxation	  induced	  by	  ACh	  in	  aortic	  rings	  from	  control	  and	  Abca1e-­‐/-­‐	  mice	  on	  a	  chow	  







Results	   	  
71	  
We	   also	   tested	   if	   the	   lack	   of	   ABCA1	   from	   the	   endothelium	   interferes	   with	  
monocyte-­‐endothelial	   interactions	   by	   an	   ex	   vivo	   approach.	  We	  harvested	   aortae	  
from	   knockout	   and	   control	   mice.	   After	   removal	   of	   peripheral	   fat	   tissue,	   aortae	  
were	  cut	  into	  small	  rings,	  which	  were	  then	  pinned	  on	  an	  agarose	  plate.	  After	  two	  
hours	  preincubation	  of	   the	  rings	   in	   the	  presence	  or	  absence	  of	  TNF-­‐alpha,	  THP1	  
monocytes	   labeled	  with	   fluorescent	  CellTracer	  CFSE	  were	  added	   for	  30	  minutes.	  
After	   washing	   with	   PBS,	   the	   numbers	   of	   adhering	   monocytes	   were	   counted	   by	  
fluorescence	   microscopy.	   Few	  monocytes	   were	   bound	   by	   unstimulated	   rings	   of	  
control	   and	   knockout	   aortae,	   as	   previously	   reported	   165.	   Stimulation	   with	   TNF-­‐
alpha	   increased	   monocyte	   adhesion	   to	   aortic	   rings	   by	   factor	   2	   compared	   to	  
unstimulated	  aortae.	  However,	  no	  difference	  in	  monocyte	  adhesion	  was	  observed	  
between	  Abca1e-­‐/-­‐and	  control	  mice	  (Figure	  34A	  and	  B).	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Figure	  34	  	  -­‐	  Effect	  of	  the	  endothelial	  ABCA1	  knock-­‐out	  on	  monocyte	  adhesion	  to	  aortic	  rings.	  	  
(A)	  En	  face	  immunofluorescence	  staining	  of	  monocytes	  bound	  to	  the	  endothelium	  of	  mouse	  aortae;	  
n=4-­‐5	  mice	  per	  group.	  Scale	  bar	  100	  µm.	  (B)	  Quantification	  of	  adhered	  monocytes	  on	  CTL	  and	  KO	  
aortae	   in	  response	   to	  TNF-­‐alpha	  pre-­‐incubation	  or	  with	  serum	  co-­‐incubation.	  Data	  represent	   the	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7.9. Endothelial	  cell	  specific	  ABCA1	  knockout	  increases	  atherosclerotic	  lesions	  
Finally,	  we	  decided	  to	  test	  the	  effect	  of	  endothelial	  ABCA1	  on	  the	  development	  of	  
atherosclerosis.	   Neither	   Abca1e-­‐/-­‐	   nor	   control	   mice	   developed	   atherosclerosis	  
upon	  feeding	  for	  12	  weeks	  with	  a	  high-­‐fat	  diet.	  To	  increase	  cholesterol	  exposure,	  
we	  crossed	  LDL	  receptor	  knockout	  (Ldlr-­‐/-­‐)	  mice	  with	  Abca1e-­‐/-­‐	  mice	  to	  generate	  
mice	   that	   are	   double	   homozygous	   for	   knockouts	   of	   the	   LDL	   receptor	   and	  
endothelial	  ABCA1	  (Abca1e-­‐/-­‐	  x	  Ldlr-­‐/-­‐).	  We	  also	  crossed	  the	  Ldlr-­‐/-­‐	  mice	  with	  the	  
VE-­‐cadherin	  cre	  mice	  to	  obtain	  single	  Ldlr-­‐/-­‐	  mice	  as	  the	  controls.	  After	  16	  weeks	  
of	   high	   cholesterol	   feeding,	   the	   two	   mouse	   strains	   demonstrated	   pronounced	  
hyperlipidemia	  which,	   however,	   did	   not	   differ	   between	   Abca1e-­‐/-­‐	   x	   Ldlr-­‐/-­‐	   and	  
Ldlr-­‐/-­‐	  mice,	   neither	   did	   they	   differ	   in	   bodyweight	   gain	   (Figure	   35	   and	  Figure	  
36A).	   Plasma	   levels	   of	   cholesterol	   and	   triglyceride	   amounted	   to	   36.27	   ±	   4.78	  
mmol/l	  and	  4.49	  ±	  1.20	  mmol/l,	  respectively,	  in	  the	  Abca1e-­‐/-­‐	  x	  Ldlr-­‐/-­‐	  mice	  and	  
to	  41.88	  ±	  4.87	  mmol/l	  and	  3.47	  ±	  1.04	  mmol/l,	  respectively,	   in	  the	  Ldlr-­‐/-­‐	  mice	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Figure	  35	  –	  Bodyweight	  gain	  and	  plasma	  parameter	  changes	  of	  Abca1e-­‐/-­‐	  x	  Ldlr-­‐/-­‐	  and	  Ldlr-­‐
/-­‐	   mice	   on	   HFHC	   diet.	   (A)	   Both	   genotypes	   increased	   their	   bodyweight	   upon	   HFHC	   diet,	   no	  
statistical	   difference	   between	   the	   groups	   was	   observed.	   (B),	   (C)	   and	   (D)	   show	   the	   value	   of	   the	  
different	  plasma	  parameters	  with	  no	  statistically	  significant	  differences	  between	  the	  groups.	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Figure	   36	   -­‐	   Dyslipidemia	   in	  mice	  with	   a	   double	   knock-­‐out	   of	   endothelial	   ABCA1	   and	   LDL	  
receptor	   (Abca1e-­‐/-­‐	   x	   Ldlr-­‐/-­‐)	   and	  mice	  with	   LDL-­‐receptor	   knock-­‐out	   (Ldlr-­‐/-­‐).	   (A)	  Plasma	  
cholesterol	   concentration	   showed	   no	   statistical	   differences	   after	   16	   weeks	   of	   HFHC	   diet	   when	  
comparing	  Abca1e-­‐/-­‐	   x	   Ldlr-­‐/-­‐	   and	  Ldlr-­‐/-­‐	  mice.	   (B)	   Cholesterol	   profile	   showed	  no	  difference	   in	  
lipoprotein	  fractions.	  Data	  represent	  the	  mean	  ±	  SEM.	  *	  P	  <	  0.05;	  n=8-­‐10	  mice	  per	  group.	  
To	   investigate	   the	   impact	   of	   endothelial	   ABCA1	   deficiency	   on	   atherosclerosis	  
development	   in	   Abca1e-­‐/-­‐x	   Ldlr-­‐/-­‐	   mice,	   two	   measurements	   of	   atherosclerosis	  
were	   conducted.	   En	   face	   aortic	   surface	   lesion	   area	   (Figure	   37A	   and	  B)	   showed	  
increased	   atherosclerosis	   in	   Abca1e-­‐/-­‐x	   Ldlr-­‐/-­‐	   mice	   compared	   to	   control.	   This	  
observation	  was	  then	  confirmed	  by	  the	  microscopic	  analysis	  of	  Oil	  red	  O–stained	  
aortic	  root	  sections,	  which	  revealed	  significantly	  higher	  lesions	  in	  Abca1e-­‐/-­‐x	  Ldlr-­‐
/-­‐	   mice	   versus	   their	   Ldlr-­‐/-­‐	   counterparts	   (0.62	   ±	   0.051	   mm2	  and	   0.56	   ±	   0.036,	  
respectively)	  (Figure	  37).	  Staining	  of	   the	  plaque	   for	  CD68	  positive	  macrophages	  
showed	  however	  no	   significant	  difference	  between	   the	   two	  groups	   (Figure	   38).	  
Taken	   together	   the	   data	   indicate	   that	   deletion	   of	   endothelial	   ABCA1	   expression	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enhances	   atherosclerotic	   lesion	   development	   in	   the	   aortic	   valve	   and	   the	   whole	  
aorta.	  	  
	  
Figure	   37	   –	   Endothelial	   ABCA1	   deletion	   increases	   atherosclerosis.	   (A)	   and	   (B)	   The	   whole	  
aorta	  was	  harvested	  and	  cut	  open.	  Atherosclerotic	  lesions	  were	  stained	  with	  Oil	  Red	  O	  (red).	  The	  
area	  covered	  by	  atherosclerotic	  lesions	  was	  significantly	  higher	  in	  Abca1e-­‐/-­‐	  x	  Ldlr-­‐/-­‐	  compared	  to	  
the	   Ldlr-­‐/-­‐	   control.	   (C)	   and	   (D)	   show	   the	   quantification	   results	   of	   the	   tricuspid	   valve	   staining,	  
where	  a	  higher	  lesion	  area	  can	  be	  observed	  in	  double	  KO	  mice.	  Scale	  bar	  500	  µm.	  *	  P	  <	  0.05;	  n=8-­‐10	  
mice	  per	  group. 
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Figure	   38	   –	   Staining	   of	   the	   plaque	   for	   CD68	   positive	  macrophages	   revealed	   no	   difference	  
between	  the	  two	  groups.	  Scale	  bar	  500	  µm;	  n=8-­‐10	  mice	  per	  group.	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8. Discussion	  
In	   this	  work,	  we	  studied	  an	  endothelial	   specific	  knockout	  mouse	  model	   to	   study	  
the	  pathophysiological	   importance	  of	  endothelial	  ABCA1	  and	   its	   interaction	  with	  
HDL	  and	  apoA-­‐I	  in	  vivo.	  These	  mice	  were	  generated	  by	  crossing	  floxed	  Abca1	  mice	  
with	  mice	  expressing	  Cre	  under	  the	  control	  of	  the	  VE-­‐Cadherin	  promoter	  150.	  The	  
specificity	   of	   the	   knockout	   was	   tested	   by	   immunofluorescence	   in	  
macrovasculature	   (Figure	   9)	   and	  microvasculature	   (Figure	   10	   and	  Figure	   11)	  
and	   with	   RCT-­‐PCR	   and	   western	   blot	   in	   various	   tissues	   (Figure	   13).	   These	  
experiments	   showed	   that	   endothelial	   cells	   of	   the	  Abca1e-­‐/-­‐	  mice	  do	  not	   express	  
ABCA1,	  whereas	   other	   cell	   types,	   including	   bone	  marrow	   derived	  macrophages,	  
were	  still	  expressing	  ABCA1	  normally.	  The	  mice	  did	  not	  have	  any	  developmental	  
problem	  or	  fecundity	  issues.	  No	  particular	  evidence	  of	  a	  perturbed	  behavior	  was	  
observed.	  	  
8.1. Role	  of	  endothelial	  ABCA1	  in	  HDL	  and	  apoA-­‐I	  metabolism	  
Many	  studies	  have	  shown	  the	  importance	  of	  liver	  and	  intestine	  ABCA1	  in	  HDL	  and	  
apoA-­‐I	   metabolism	   110,116.	   The	   reported	   data	   suggest	   that	   these	   two	   organs	  
contribute	   to	   the	   majority	   of	   HDL	   production.	   In	   line	   with	   these	   observations,	  
endothelial	  ABCA1	  knockout	  mice	  did	  not	  lead	  to	  differences	  in	  lipoprotein	  plasma	  
concentrations	   either	   on	   chow	   or	   high	   fat	   diet.	   We	   have	   also	   demonstrated	   by	  
FPLC	  that	  the	  particle	  size	  of	  VLDL,	  LDL	  and	  HDL	  was	  not	  altered	  by	  the	  absence	  of	  
endothelial	   ABCA1.	   Triglyceride	   and	   phospholipid	   plasma	   concentration	   did	   not	  
differ	  compared	  to	  control	  mice.	  	  
We	  have	  previously	  shown	  by	  RNA	  interference	  that	  ABCA1	  is	  a	  limiting	  factor	  for	  
the	   transcytosis	   of	   apoA-­‐I	   through	   cultivated	   aortic	   endothelial	   cells	   118.	  
Furthermore,	  the	  apoA-­‐I[L218/L219/V221/L222]	  mutant,	  which	  does	  not	  interact	  
with	  ABCA1	  and	  does	  not	  elicit	  ABCA1	  mediated	  lipid	  efflux,	  was	  not	  internalized	  
and	  transported	  by	  aortic	  endothelial	  cells.	  Since	  this	  defect	  could	  be	  bypassed	  by	  
cell-­‐free	   pre-­‐lipidation,	   we	   postulated	   that	   ABCA1	   promotes	   transendothelial	  
transport	   of	   apoA-­‐I	   by	   forming	   HDL-­‐like	   particles	   that	   are	   trafficked	   through	  
endothelial	   cells	   by	   processes,	   which	   are	   facilitated	   by	   SR-­‐BI,	   ABCG1	   and	   EL	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91,146,147.	   In	   agreement	  with	   a	   rate-­‐limiting	   impact	   of	  ABCA1	   for	   transendothelial	  
transport,	   our	   turnover	   studies	   found	   reduced	   accumulation	   of	   exogenous	  
radioiodinated	   apoA-­‐I	   in	   the	   aorta	   of	   Abca1e-­‐/-­‐	   mice	   (Figure	   20).	   Since	   the	  
plasma	   residence	   time	  of	   125I-­‐apoA-­‐I	   did	  not	   differ	   between	  Abca1e-­‐/-­‐	  mice	   and	  
control	   mice,	   the	   reduced	   apoA-­‐I	   accumulation	   in	   the	   vascular	   wall	   does	   not	  
appear	   to	   be	   due	   to	   reduced	   exposure	   time	   but	   instead	   may	   be	   explained	   by	  
altered	   trafficking	   into	   or	   out	   of	   the	   vascular	   wall.	   A	   control	   experiment	   was	  
performed	   with	   albumin	   and	   LDL,	   which	   does	   not	   interact	   with	   ABCA1,	   and	  
showed	  no	  difference	  in	  aortic	  uptake	  (Figure	  21).	  	  
The	  difference	  between	  Abca1e-­‐/-­‐	  and	  control	  mice	  was	  neither	  seen	  in	  turnover	  
studies	  using	  the	  apoA-­‐I[L218/L219/V221/L222]	  mutant	  (Figure	  23),	  which	  does	  
not	  elicit	  ABCA1	  mediated	  lipid	  efflux	  and	  is	  not	  transported	  through	  endothelial	  
cells91,146,147.	   These	   observations	   specifically	   highlight	   the	   importance	   of	  
endothelial	   apoA-­‐I/ABCA1	   interactions	   for	   the	   occurrence	   of	   apoA-­‐I	   in	   the	  
vascular	  wall.	   From	  a	  more	   general	   perspective,	   these	   findings	   indicate	   that	   the	  
transport	   of	   proteins	   through	   the	   endothelium,	   of	   at	   least	   some	   vascular	   beds,	  
notably	  the	  aorta,	  is	  not	  merely	  filtration	  by	  size,	  as	  it	  has	  been	  described	  for	  the	  
microvasculature	  by	  the	  two-­‐pore-­‐model	  173,	  but	  a	  more	  regulated	  process.	  	  
8.2. Role	  of	  endothelial	  ABCA1	  in	  microvasculature	  and	  lymphatics	  	  
The	   lower	  abundance	  of	  apoA-­‐I	  within	   the	  aortic	  wall	  can	  be	   the	  result	  of	  either	  
decreased	  entry	  or	  increased	  exit.	  In	  fact,	  recently,	  lymphatic	  vessels	  were	  shown	  
to	  be	  rate	  limiting	  for	  the	  removal	  of	  HDL	  from	  extravascular	  tissues,	  including	  the	  
aorta,	   and	   the	   anti-­‐atherogenicity	   of	   apoA-­‐I	   in	   mice	   163,171.	   Consequently,	   we	  
extensively	  characterized	  the	  structure	  and	  function	  of	  the	  lymphatic	  vasculature	  
in	  Abca1e-­‐/-­‐	  mice	  versus	  control	  mice.	  We	  did	  not	  observe	  any	  differences	  in	  the	  
number,	  morphology,	   and	   functionality	   of	   lymphatic	   vessels	   between	   Abca1e-­‐/-­‐	  
and	  control	  mice.	  
Using	  the	  same	  model	  in	  which	  Angeli	  and	  colleagues	  showed	  the	  limiting	  effect	  of	  
SR-­‐BI	   for	   HDL	   lymphatic	   transport	   out	   of	   the	   footpad	   163,	   we	   did	   not	   find	   any	  
difference	  between	  Abca1e-­‐/-­‐	  and	  control	  mice	  in	  the	  appearance	  of	  radiolabeled	  
apoA-­‐I	   or	   HDL	   either	   in	   the	   popliteal	   lymph	   nodes	   or	   in	   plasma.	   Lymphatic	  
function	  did	  not	  seem	  to	  be	  altered	  by	  the	  absence	  of	  ABCA1	  in	  the	  endothelium	  as	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quantitative	  real-­‐time	   imaging	  of	   lymphatic	  clearance	  of	   fluorescent	  apoA-­‐I	   from	  
the	  mouse	  paw	  neither	   revealed	  any	  differences	  between	  Abca1e-­‐/-­‐	   and	   control	  
mice.	   The	   transport	   of	   radioactive	   apoA-­‐I	   from	   the	   peritoneum	   into	   the	  
bloodstream,	  which	  is	  mainly	  accomplished	  by	  the	  lymphatic	  system	  via	  either	  the	  
thoracic	   duct	   or	   the	   right	   lymphatic	   duct	   174,	   was	   also	   similar	   for	   endothelial	  
ABCA1	  knockout	  and	  control	  mice.	  Transport	  of	  125I-­‐apoA-­‐I	  from	  the	  blood	  stream	  
into	  the	  peritoneum,	  which	  is	  accomplished	  by	  capillaries	  175	  through	  two	  kinds	  of	  
pores	  differing	  by	  size,	  	  was	  also	  independent	  of	  endothelial	  ABCA1	  expression.	  	  
For	   mediating	   cholesterol	   efflux	   from	   macrophages	   and	   RCT,	   HDL	   has	   to	   pass	  
through	  endothelial	  layers	  twice,	  first	  to	  enter	  the	  extravascular	  space	  and	  second	  
to	   return	   to	   the	   bloodstream.	  We	   therefore	   tested	   the	   impact	   of	   the	   absence	   of	  
endothelial	   ABCA1	   on	   macrophage	   to	   feces	   reverse	   cholesterol	   transport	   using	  
two	   approaches.	   The	   first	   approach	   was	   first	   described	   by	   Rader	   et	   al	   162.	   We	  
injected	  macrophages	  radioactively	  loaded	  with	  cholesterol	  i.p.	  and	  measured	  the	  
appearance	   of	   radioactive	   cholesterol	   in	   the	   plasma	   as	  well	   as	   the	   liver	   and	   the	  
feces.	   The	   second	   RCT	  was	   first	   described	   by	   Lim	   et	   al.	   163	   to	   study	   the	   role	   of	  
lymphatics.	  We	   injected	   the	   cholesterol	   loaded	  macrophages	   into	   the	   footpad	   of	  
the	  mice.	  In	  agreement	  with	  the	  maintained	  lymphatic	  and	  microvascular	  function,	  
the	   reverse	   transport	   of	   cholesterol	   from	   macrophages	   injected	   either	   into	   the	  
peritoneum	  or	  into	  the	  footpad	  led	  to	  normal	  fecal	  sterol	  excretion.	  
8.3. Role	  of	  endothelium	  ABCA1	  in	  atherosclerosis	  and	  endothelial	  function	  
ABCA1	   plays	   a	   crucial	   role	   in	   the	   regulation	   of	   cellular	   cholesterol	   homeostasis	  
and	  the	  formation	  of	  HDL.	  Many	  mutations	  in	  the	  human	  ABCA1	  gene,	  as	  well	  the	  
knockout	   of	   the	   ABCA1	   gene	   in	   mice,	   dose-­‐dependently	   lower	   HDL	   cholesterol	  
levels	  and	  promote	  the	  accumulation	  of	  cellular	  lipids	  notably	  in	  macrophages	  176.	  
Nevertheless,	   the	   importance	   of	   ABCA1	   for	   atherosclerosis	   is	   not	   unequivocally	  
resolved.	  Several,	  but	  not	  all,	  case	  reports	  on	  patients	  with	  Tangier	  disease,	  as	  well	  
as	   imaging	   studies	   in	   families	   with	   ABCA1	   mutations,	   indicate	   increased	  
cardiovascular	  risk	  in	  carriers	  of	  ABCA1	  mutations,	  notably	  if	  associated	  with	  low	  
HDL	   cholesterol	   177–179.	   By	   contrast,	   population-­‐wide	   Mendelian	   randomization	  
studies	  identified	  ABCA1	  mutation	  carriers	  at	  a	  prevalence	  of	  0.3%	  who,	  however,	  
had	  no	   increased	   cardiovascular	   risk	  despite	   reduced	  HDL-­‐cholesterol	   levels	   180.	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Interestingly,	   the	   same	   studies	   identified	  ABCA1	  mutations,	  which	  did	  not	   affect	  
HDL	  cholesterol	  levels	  but	  increased	  cardiovascular	  risk	  180.	  A	  similar	  dissociation	  
of	   HDL	   cholesterol	   and	   atherosclerosis	   was	   observed	   in	   mice	   with	   systemic	   or	  
targeted	   knockout	   of	   ABCA1.	   The	   complete	   ABCA1	   knockout	   caused	   HDL	  
deficiency	   and	   lowered	   apoB	   lipoprotein	   cholesterol	   concentrations	   in	   apoE-­‐	   or	  
LDL-­‐receptor	   knockout	   conditions,	   which	   mitigated	   any	   atherogenic	   effect	   of	  
ABCA1	   deficiency	   181.	   Liver-­‐specific	   ABCA1	   knockout	   decreased	  HDL	   cholesterol	  
levels	  by	  more	  than	  80%,	  but	  had	  no	  impact	  on	  atherosclerosis	  112.	  	  
Conversely,	   the	   knockout	   of	   macrophage	   ABCA1	   in	   Ldlr-­‐/-­‐	   mice,	   as	   well	   as	  
transplantation	   of	   ABCA1	   deficient	   bone	   marrow	   into	   irradiated	   Ldlr-­‐/-­‐	   mice,	  
moderately	   increased	   atherosclerosis	   without	   changing	   HDL-­‐cholesterol	   levels	  
103,182,183.	   These	   data	   indicate	   that	   ABCA1	   modulates	   atherosclerosis	   by	   local	  
rather	  than	  by	  systemic	  effects	  mirrored	  by	  HDL	  cholesterol	  levels.	  In	  agreement	  
with	   this	  notion,	  we	  here	  report	   increased	  atherosclerosis	   in	  Abca1e-­‐/-­‐	  x	  Ldlr-­‐/-­‐	  
vs	  Ldlr-­‐/-­‐	  mice,	  as	  shown	  with	  Oil	  red	  O	  staining	  of	  the	  aortic	  valves	  and	  the	  whole	  
aorta	  (Figure	  37).	  Our	  data	  support	  the	  findings	  of	  Remaley	  and	  colleagues	  who	  
overexpressed	  an	  ABCA1	  transgene	  in	  mice	  using	  the	  Tie2	  promoter.	  The	  resulting	  
overexpression	  of	  ABCA1	  in	  endothelial	  cells	  reduced	  the	  mild	  atherosclerosis	  of	  
mice	  fed	  with	  a	  high	  fat	  diet,	  but	  not	  the	  more	  pronounced	  atherosclerosis	  of	  apoE	  
knockout	  mice	  120.	  
Although	   Remaley	   and	   colleagues	   did	   not	   find	   the	   transgene	   expressed	   in	  
peritoneal	   macrophages	   of	   their	   mice,	   it	   is	   important	   to	   note	   that	   the	   Tie2	  
promoter	   is	   also	   active	   in	  myeloid	   cells	   184.	   It	   is	   important	   to	   note	   that	   neither	  
single	   Abca1e-­‐/-­‐	   mice	   nor	   double	   Abca1e-­‐/-­‐	   x	   Ldlr-­‐/-­‐	   mice	   differed	   from	   the	  
respective	   ABCA1	   expressing	   control	   mice	   by	   plasma	   lipid	   concentrations	   or	  
lipoprotein	   distributions.	   This	   is	   in	   contrast	   to	   the	   increased	   HDL	   cholesterol	  
levels	   previously	   observed	   in	   mice	   overexpressing	   an	   ABCA1	   transgene	   in	  
endothelial	   cells	  under	   the	   control	  of	   the	  Tie2	  promoter	   120.	   Thus,	   the	  enhanced	  
atherosclerosis	  observed	  by	  us	  in	  Abca1e-­‐/-­‐	  x	  Ldlr-­‐/-­‐	  mice	  appears	  to	  result	  from	  
local	   endothelial	   dysfunction.	   In	   fact,	   under	   both	   chow	   and	   HFHC	   diets	   the	  
endothelium-­‐dependent	   vasodilation	   of	   aortic	   rings	   from	   Abca1e-­‐/-­‐	   mice	   was	  
compromised,	  as	  compared	  to	  those	  from	  ABCA1	  expressing	  control	  mice	  (Figure	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33).	  These	  findings	  are	  in	  agreement	  with	  those	  made	  by	  Terasaka	  et	  al	  69	  in	  mice	  
with	  a	  total	  knockout	  of	  ABCA1,	  as	  well	  as	  by	  Bisoendial	  et	  al	  185	  	  in	  humans	  with	  
mutations	  in	  ABCA1.	  However,	  in	  these	  settings	  it	  was	  not	  clear	  whether	  the	  lack	  
of	   ABCA1	   in	   the	   endothelium	   or	   the	   low	   concentrations	   of	   HDL	   contributed	   to	  
endothelial	   dysfunction.	   Our	   findings	   clearly	   emphasize	   the	   role	   of	   ABCA1	  
independently	  of	  HDL.	  We	  did	  not	  observe	  any	  difference	   in	  basal	  or	  TNF−alpha	  
stimulated	  monocyte	   adhesion	   to	   aortic	   rings	   of	   Abca1e-­‐/-­‐	   and	   control	  mice.	   At	  
first	  sight,	  this	  is	  in	  contrast	  to	  in	  vitro	  experiments,	  which	  found	  that	  HDL	  inhibits	  
VCAM-­‐1	   expression	   and	   monocyte	   adhesion	   33.	   However,	   HDL	   exerts	   this	   anti-­‐
inflammatory	   effect	   by	  ABCA1	   independent	  mechanisms	   186	   involving	   SR-­‐BI	   and	  
3β-­‐hydroxysteroid-­‐Δ24	   reductase,	   as	  well	   as	   sphingosine-­‐1-­‐phosphate	  mediated	  
Akt	  signaling	  62,187.	  
8.4. Role	  of	  endothelial	  ABCA1	  in	  glucose	  metabolism	  
	  And	   interesting	   side	   finding	   of	   our	   mouse	   mode	   is	   the	   intraperitoneal	   glucose	  
tolerance.	  It	  has	  been	  shown	  that	  pancreatic	  ABCA1	  plays	  a	  critical	  role	  in	  insulin	  
secretion	  and	  impairment	  of	  glucose	  tolerance	  167.	  The	  reason	  is	  the	  regulation	  of	  
cholesterol	   distribution	   within	   beta-­‐cells	   appears	   to	   be	   crucial	   for	   regulating	  
insulin	  secretion.	  Interestingly,	  in	  our	  study,	  the	  glucose	  plasma	  concentration	  was	  
not	   changed	   in	   the	   knockout	   mice.	   We	   observed	   an	   improved	   response	   in	   the	  
glucose	  tolerance	  test	  in	  Abca1e-­‐/-­‐	  mice	  compared	  to	  control.	  This	  difference	  was	  
even	  more	   pronounced	   after	   a	   HFHC	   diet	   feeding.	   The	   reason	   of	   this	   particular	  
observation	   is	   still	   unknown.	   Recent	   studies	   have	   shown	   a	   clear	   link	   between	  
endothelial	  cells	  and	  pancreatic	   islets	  168.	   It	  has	  been	  shown	  that	   throughout	  the	  
development,	  islet	  endothelial	  cells	  are	  involved	  in	  not	  only	  the	  delivery	  of	  oxygen	  
and	  nutrients	   to	   endocrine	   cells,	   but	   also	   induce	   insulin	   gene	   expression	  during	  
islet	  development,	  affect	  adult	  beta	  cell	   function,	  promote	  beta	  cell	  proliferation,	  
and	  produce	   a	   number	   of	   vasoactive,	   angiogenic	   substances	   and	   growth	   factors.	  
Therefore,	   further	   experiments	   showing	   the	   influence	   of	   endothelial	   ABCA1	   and	  
pancreatic	   islet	   insulin	   production	   are	   needed	   to	   confirm	   our	   observation	   of	   an	  
improved	   GTT	   in	   the	   knockout	   mice	   and	   ,	   if	   so,	   to	   unravel	   the	   underlying	  
mechanism.	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9. Conclusion	  and	  Outlook	  
In	   conclusion,	   by	   using	   a	   targeted	   knockout	  mouse	  model,	  we	   here	   provide	   the	  
first	  direct	  evidence	  that	  endothelial	  ABCA1	  promotes	  local	  vasodilation	  and	  anti-­‐
atherogenic	   activities,	   which	   are	   independent	   of	   plasma	   HDL	   cholesterol	   levels.	  
Notably,	   the	   reduced	   accumulation	   of	   apoA-­‐I	   in	   the	   vascular	   wall	   of	   Abca1e-­‐/-­‐	  
mice	  supports	  the	  concept	  that	  transendothelial	  transport	  of	  apoA-­‐I	  and	  HDL	  into	  
the	  arterial	  wall	  is	  a	  regulated	  process.	  	  
Confirming	  the	  observation	  made	  on	  atherosclerosis	  using	  a	  different	  atherogenic	  
murine	   model,	   such	   as	   apoE	   knockout	   mouse,	   might	   be	   of	   interest	   for	   future	  
experiments.	  However,	   since	  ABCA1	  plays	   some	  role	   in	   cellular	  apoE	   trafficking,	  
the	   absence	   of	   apoE	   might	   also	   mask	   any	   effect	   of	   ABCA1	   beyond	   of	  
hyperlipidemia.	   More	   importantly,	   an	   overexpression	   of	   human	   apoA-­‐I	   using	  
adeno-­‐associated	   virus	   188	   to	   rescue	   atherosclerosis	   on	   Ldlr-­‐/-­‐,	   but	   not	   on	   the	  
Abca1e-­‐/-­‐	  x	  Ldlr-­‐/-­‐,	  would	  be	  an	  additional	  proof	  that	  endothelial	  ABCA1	  confers	  
atheroprotection.	  
Finding	   another	  method	   to	   show	   the	   reduced	  uptake	   of	   apoA-­‐I	  within	   the	   aorta	  
would	  also	  be	  an	  important	  tool.	  Recently,	   in	  vivo	  MRI	  imaging	  of	  atherosclerotic	  
plaque	  using	  HDL	   labelled	  with	  superparamagnetic	   iron	  oxide	  nanoparticles	  and	  
quantum	  dots	  has	  been	  shown	  to	  be	  possible	  189.	  Using	  this	  technique	  in	  order	  to	  
visualize	   the	   deposition	   of	   labeled	  HDL	   or	   apoA-­‐I	  within	   the	   aorta	  would	   be	   an	  
interesting	  tool	  that	  could	  confirm	  our	  observation.	  	  
In	  the	  next	  step,	  it	  will	  be	  important	  to	  investigate,	  for	  transendothelial	  apoA-­‐I	  and	  
HDL	  transport	  in	  vivo	  as	  well	  as	  atherosclerosis,	  the	  importance	  of	  other	  receptors,	  
such	  as	  SR-­‐BI	  and	  ABCG1.	  Ideally,	  this	  is	  done	  following	  the	  same	  procedure	  as	  for	  
this	  project,	  namely	  developing	  an	  endothelium	  specific	  knockout	  of	  SR-­‐BI,	  EL	  or	  
ABCG1.	   Especially	   for	   SR-­‐BI	   this	   strategy	   is	   important,	   because	   the	   total	   SR-­‐BI	  
knockout	   increases	   the	   concentration	   and	   size	   of	   HDL	   136,	   which	   in	   turn	   may	  
interfere	  with	   the	   transport.	   For	   ABCG1	   this	   problem	  may	   be	   of	   low	   relevance,	  
since	   ABCG1	   does	   not	   alter	   HDL-­‐levels	   and	   particle	   distribution	   190.	   EL	   is	  
predominantly	  expressed	   in	  endothelial	   cells	   191,	   so	   that	  an	  endothelium	  specific	  
knock-­‐out	  may	  also	  be	  less	  relevant.	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